// ============================================================
// TERRAIN — Competitor Database
// lib/data/competitor-database.ts
//
// Static database of competitive assets organized by indication.
// Each record represents a drug/biologic in development or on market.
// Sources: ClinicalTrials.gov, FDA, SEC filings, company pipelines,
// Evaluate Pharma, BioCentury (2020-2025)
// ============================================================

import type { ClinicalPhase } from '@/types';

// Modular competitor data by therapy area
import { ONCOLOGY_EXTRA_COMPETITORS } from './competitor-data-oncology-2';
import { NEUROLOGY_COMPETITORS } from './competitor-data-neurology';
import { RARE_DISEASE_COMPETITORS } from './competitor-data-rare-disease';
import { IMMUNOLOGY_COMPETITORS } from './competitor-data-immunology';
import { CARDIO_METABOLIC_COMPETITORS } from './competitor-data-cardio-metabolic';
import { SPECIALTY_COMPETITORS_1 } from './competitor-data-specialty-1';
import { SPECIALTY_COMPETITORS_2 } from './competitor-data-specialty-2';
import { ADDITIONAL_COMPETITORS } from './competitor-data-additional';

// ────────────────────────────────────────────────────────────
// COMPETITOR RECORD TYPE
// ────────────────────────────────────────────────────────────

export interface CompetitorRecord {
  asset_name: string;
  generic_name?: string;
  company: string;
  indication: string;                    // Normalized indication name
  indication_specifics: string;          // Exact label or trial population
  mechanism: string;                     // Human-readable mechanism
  mechanism_category: string;            // Normalized category for grouping
  molecular_target?: string;
  phase: ClinicalPhase;
  primary_endpoint?: string;
  key_data?: string;
  line_of_therapy?: string;              // "1L", "2L", "2L+", "maintenance", "adjuvant", "neoadjuvant"
  partner?: string;
  nct_ids?: string[];
  first_in_class: boolean;
  orphan_drug: boolean;
  has_biomarker_selection: boolean;
  strengths: string[];
  weaknesses: string[];
  source: string;
  last_updated: string;
}

// ────────────────────────────────────────────────────────────
// COMPETITOR DATA
// ────────────────────────────────────────────────────────────

const BASE_COMPETITORS: CompetitorRecord[] = [

  // ══════════════════════════════════════════════════════════
  // NON-SMALL CELL LUNG CANCER (NSCLC)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L NSCLC, PD-L1 TPS >= 1%, monotherapy or + chemo',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-024/189: OS benefit in 1L NSCLC with PD-L1 >= 50% (HR 0.63) and + chemo (HR 0.49)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Dominant 1L market share', 'Broadest label across tumor types', 'Extensive combination data'],
    weaknesses: ['LOE approaching 2028', 'Diminishing PFS/OS gains in unselected populations'],
    source: 'FDA label; KEYNOTE trials; Merck 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Opdivo',
    generic_name: 'nivolumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L NSCLC + ipilimumab + chemo or monotherapy 2L+',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate-9LA: 1L NSCLC OS with nivo + ipi + chemo (HR 0.73 at 4-year follow-up)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong brand', 'IO-IO combination strategy', 'Long-term survival data'],
    weaknesses: ['Trailing Keytruda in NSCLC market share', 'Complex dosing with ipilimumab'],
    source: 'FDA label; CheckMate trials; BMS 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tagrisso',
    generic_name: 'osimertinib',
    company: 'AstraZeneca',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L EGFR-mutated (ex19del, L858R) NSCLC',
    mechanism: '3rd-gen EGFR TKI',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'EGFR',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'FLAURA: 1L EGFR+ NSCLC PFS 18.9 vs 10.2 mo (HR 0.46); FLAURA2: + chemo PFS 25.5 mo',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Gold standard in EGFR+ NSCLC', 'CNS penetration', 'Adjuvant indication'],
    weaknesses: ['Resistance mutations (C797S)', 'Limited to EGFR-mutated population'],
    source: 'FDA label; FLAURA/FLAURA2 trials; AZ 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lumakras',
    generic_name: 'sotorasib',
    company: 'Amgen',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '2L+ KRAS G12C-mutated NSCLC after prior systemic therapy',
    mechanism: 'KRAS G12C inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'KRAS G12C',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'CodeBreaK 200: ORR 28.1% vs 13.2% docetaxel; PFS 5.6 vs 4.5 mo (HR 0.66)',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First-in-class KRAS G12C', 'Oral dosing', 'Biomarker-selected'],
    weaknesses: ['Modest ORR', 'No OS benefit demonstrated', 'Narrow patient segment (~13% of NSCLC)'],
    source: 'FDA label; CodeBreaK trials; Amgen 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Krazati',
    generic_name: 'adagrasib',
    company: 'Mirati/BMS',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '2L+ KRAS G12C-mutated NSCLC',
    mechanism: 'KRAS G12C inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'KRAS G12C',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'KRYSTAL-1: ORR 42.9% in 2L NSCLC; CNS activity demonstrated; KRYSTAL-7 1L ongoing',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Higher ORR than sotorasib', 'CNS penetration', 'Longer half-life'],
    weaknesses: ['GI/hepatic toxicity signal', 'Accelerated approval — confirmatory trial needed'],
    source: 'FDA label; KRYSTAL trials; Mirati/BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Alecensa',
    generic_name: 'alectinib',
    company: 'Roche/Genentech',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L ALK-positive NSCLC',
    mechanism: 'ALK inhibitor (2nd-gen)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'ALK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ALEX: PFS 34.8 vs 10.9 mo vs crizotinib (HR 0.43); CNS efficacy 81% ORR',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Superior PFS in ALK+', 'Excellent CNS activity', 'Well-tolerated'],
    weaknesses: ['Limited to ALK+ population (~5% of NSCLC)', 'Resistance develops'],
    source: 'FDA label; ALEX trial; Roche 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lorbrena',
    generic_name: 'lorlatinib',
    company: 'Pfizer',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L ALK-positive NSCLC',
    mechanism: '3rd-gen ALK/ROS1 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'ALK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'CROWN: 1L ALK+ PFS NR vs 9.3 mo crizotinib at 3 yr (HR 0.27); 5-yr PFS 60%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Best-in-class PFS in ALK+', 'Active against most ALK resistance mutations', 'CNS penetration'],
    weaknesses: ['CNS side effects (cognitive, mood)', 'Hyperlipidemia', 'Small addressable population'],
    source: 'FDA label; CROWN trial; Pfizer 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Imfinzi',
    generic_name: 'durvalumab',
    company: 'AstraZeneca',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: 'Stage III unresectable NSCLC after CRT; 1L extensive-stage SCLC',
    mechanism: 'PD-L1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'PACIFIC: Stage III NSCLC PFS 16.8 vs 5.6 mo (HR 0.52); 5-yr OS 42.9%',
    line_of_therapy: 'maintenance',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Dominant in Stage III consolidation', 'Long-term survival data', 'Expanding to biliary/bladder'],
    weaknesses: ['Limited 1L metastatic NSCLC share', 'Competition from Keytruda combinations'],
    source: 'FDA label; PACIFIC trial; AZ 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rybrevant',
    generic_name: 'amivantamab',
    company: 'Johnson & Johnson',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: 'EGFR exon 20 insertion NSCLC; 1L with lazertinib',
    mechanism: 'EGFR-MET bispecific antibody',
    mechanism_category: 'bispecific',
    molecular_target: 'EGFR/MET',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'MARIPOSA: 1L EGFR+ with lazertinib PFS 23.7 vs 16.6 mo vs Tagrisso (HR 0.70)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First bispecific in NSCLC', 'Superiority vs Tagrisso in combination', 'Novel mechanism for EGFR ex20ins'],
    weaknesses: ['IV administration', 'Infusion reactions', 'VTE risk'],
    source: 'FDA label; MARIPOSA/CHRYSALIS trials; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Dato-DXd',
    generic_name: 'datopotamab deruxtecan',
    company: 'Daiichi Sankyo/AstraZeneca',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '2L+ non-squamous NSCLC after platinum-based chemo + IO',
    mechanism: 'ADC (Trop-2)',
    mechanism_category: 'adc',
    molecular_target: 'TROP2',
    phase: 'Phase 3',
    primary_endpoint: 'OS',
    key_data: 'TROPION-Lung01: PFS 4.4 vs 3.7 mo vs docetaxel (HR 0.75); OS data immature',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Novel ADC platform in NSCLC', 'Potential 1L combinations', 'Manageable toxicity'],
    weaknesses: ['Modest PFS improvement', 'ILD/pneumonitis risk', 'No OS benefit yet'],
    source: 'TROPION-Lung01 (NCT04656652); ASCO 2024',
    last_updated: '2024-12-01',
  },
  {
    asset_name: 'Ivonescimab',
    generic_name: 'ivonescimab',
    company: 'Akeso/Summit Therapeutics',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L PD-L1+ NSCLC monotherapy',
    mechanism: 'PD-1/VEGF bispecific antibody',
    mechanism_category: 'bispecific',
    molecular_target: 'PD-1/VEGF',
    phase: 'Phase 3',
    primary_endpoint: 'PFS',
    key_data: 'HARMONi-2: 1L PD-L1+ NSCLC PFS 11.1 vs 7.1 mo vs pembrolizumab (HR 0.51)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Head-to-head superiority vs Keytruda', 'Novel dual mechanism', 'Anti-angiogenic IO combination in single molecule'],
    weaknesses: ['China-centric data (generalizability)', 'US confirmatory trials ongoing', 'Manufacturing complexity'],
    source: 'HARMONi-2 (NCT05499390); WCLC 2024',
    last_updated: '2024-11-01',
  },

  // ══════════════════════════════════════════════════════════
  // BREAST CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Enhertu',
    generic_name: 'trastuzumab deruxtecan',
    company: 'Daiichi Sankyo/AstraZeneca',
    indication: 'HER2-Positive Breast Cancer',
    indication_specifics: 'HER2+ and HER2-low metastatic breast cancer',
    mechanism: 'ADC (HER2)',
    mechanism_category: 'adc',
    molecular_target: 'HER2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'DESTINY-Breast03: HER2+ PFS 28.8 vs 6.8 mo vs T-DM1; DESTINY-Breast04: HER2-low PFS 9.9 vs 5.1 mo',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Paradigm-shifting HER2-low activity', 'Deep responses', 'Expanding indications'],
    weaknesses: ['ILD/pneumonitis risk', 'IV administration', 'High cost'],
    source: 'FDA label; DESTINY-Breast trials; Daiichi Sankyo 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Trodelvy',
    generic_name: 'sacituzumab govitecan',
    company: 'Gilead',
    indication: 'Triple Negative Breast Cancer',
    indication_specifics: 'TNBC 2L+; HR+/HER2- after endocrine + 2 chemos',
    mechanism: 'ADC (Trop-2)',
    mechanism_category: 'adc',
    molecular_target: 'TROP2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ASCENT: TNBC PFS 5.6 vs 1.7 mo (HR 0.41); TROPiCS-02: HR+ PFS 5.5 vs 4.0 mo (HR 0.66)',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First Trop-2 ADC approved', 'Activity in TNBC and HR+', 'Established safety profile'],
    weaknesses: ['Neutropenia/diarrhea', 'Modest PFS gains in HR+', 'Competition from Enhertu'],
    source: 'FDA label; ASCENT/TROPiCS-02 trials; Gilead 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Verzenio',
    generic_name: 'abemaciclib',
    company: 'Eli Lilly',
    indication: 'HER2-Positive Breast Cancer',
    indication_specifics: 'HR+/HER2- early and metastatic breast cancer',
    mechanism: 'CDK4/6 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'CDK4/6',
    phase: 'Approved',
    primary_endpoint: 'iDFS',
    key_data: 'monarchE: adjuvant HR+/HER2- high-risk iDFS HR 0.664; 5-yr absolute benefit ~7.6%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Only CDK4/6i with adjuvant approval', 'Single-agent activity', 'Strong clinical franchise'],
    weaknesses: ['Diarrhea burden', 'Competition from Ibrance/Kisqali', 'Ki-67 biomarker debate'],
    source: 'FDA label; monarchE trial; Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Kisqali',
    generic_name: 'ribociclib',
    company: 'Novartis',
    indication: 'HER2-Positive Breast Cancer',
    indication_specifics: 'HR+/HER2- metastatic breast cancer + aromatase inhibitor or fulvestrant',
    mechanism: 'CDK4/6 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'CDK4/6',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'MONALEESA-2/3/7: OS benefit across subgroups; only CDK4/6i with OS benefit in 1L pre/peri-menopausal',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['OS benefit demonstrated', 'Broad population coverage', 'NATALEE adjuvant data emerging'],
    weaknesses: ['QTc prolongation monitoring', 'Neutropenia management', 'Ibrance generic erosion pulling class pricing down'],
    source: 'FDA label; MONALEESA trials; Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'ARV-471',
    generic_name: 'vepdegestrant',
    company: 'Arvinas/Pfizer',
    indication: 'HER2-Positive Breast Cancer',
    indication_specifics: 'HR+/HER2- metastatic breast cancer, post-CDK4/6i',
    mechanism: 'Oral ER PROTAC degrader',
    mechanism_category: 'degrader',
    molecular_target: 'Estrogen Receptor',
    phase: 'Phase 3',
    primary_endpoint: 'PFS',
    key_data: 'Phase 1/2: ORR 33% with palbociclib combo in CDK4/6i-pretreated patients',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First oral ER degrader (PROTACs)', 'Novel mechanism for ESR1 mutations', 'Pfizer partnership validates approach'],
    weaknesses: ['Phase 3 data pending', 'Competition from next-gen oral SERDs', 'Novel modality risk'],
    source: 'VERITAC-2 (NCT05654623); Arvinas/Pfizer 2024',
    last_updated: '2024-11-01',
  },

  // ══════════════════════════════════════════════════════════
  // MULTIPLE MYELOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Darzalex Faspro',
    generic_name: 'daratumumab/hyaluronidase',
    company: 'Johnson & Johnson',
    indication: 'Multiple Myeloma',
    indication_specifics: '1L through 4L+ multiple myeloma; multiple combination regimens',
    mechanism: 'Anti-CD38 monoclonal antibody (SC)',
    mechanism_category: 'anti_cd38',
    molecular_target: 'CD38',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'MAIA: 1L NDMM PFS 61.9 vs 34.4 mo (HR 0.55); frontline backbone for most regimens',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Standard-of-care backbone', 'Broadest indications in MM', 'SC formulation convenience'],
    weaknesses: ['Class saturation with Sarclisa', 'High utilization means limited growth', 'Resistance in late lines'],
    source: 'FDA label; MAIA trial; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tecvayli',
    generic_name: 'teclistamab',
    company: 'Johnson & Johnson',
    indication: 'Multiple Myeloma',
    indication_specifics: 'R/R MM after >= 4 prior lines including PI, IMiD, and anti-CD38',
    mechanism: 'BCMAxCD3 bispecific',
    mechanism_category: 'bispecific',
    molecular_target: 'BCMA',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'MajesTEC-1: ORR 63%; CR rate 39.4% in heavily pretreated MM; 18.4 mo median DOR',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Off-the-shelf bispecific (no manufacturing delay)', 'Deep responses in late-line', 'Moving to earlier lines'],
    weaknesses: ['CRS and ICANS risk', 'Infections from T-cell engagement', 'Step-up dosing required'],
    source: 'FDA label; MajesTEC-1 trial; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Carvykti',
    generic_name: 'ciltacabtagene autoleucel',
    company: 'Johnson & Johnson/Legend Biotech',
    indication: 'Multiple Myeloma',
    indication_specifics: 'R/R MM after >= 1 prior line (CARTITUDE-4); 4L+ (initial)',
    mechanism: 'BCMA-directed CAR-T',
    mechanism_category: 'car_t',
    molecular_target: 'BCMA',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'CARTITUDE-4: 2L+ PFS 15-mo rate 76% vs 49% (HR 0.26); CARTITUDE-1: ORR 98%',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Deepest responses in MM history', 'MRD negativity > 60%', 'Moving to earlier lines'],
    weaknesses: ['Manufacturing vein-to-vein time', 'CRS/ICANS/parkinsonism', 'Limited manufacturing capacity'],
    source: 'FDA label; CARTITUDE trials; J&J/Legend 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Abecma',
    generic_name: 'idecabtagene vicleucel',
    company: 'Bristol-Myers Squibb/2seventy bio',
    indication: 'Multiple Myeloma',
    indication_specifics: 'R/R MM after >= 2 prior lines (KarMMa-3)',
    mechanism: 'BCMA-directed CAR-T',
    mechanism_category: 'car_t',
    molecular_target: 'BCMA',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'KarMMa-3: 2L+ PFS 13.3 vs 4.4 mo (HR 0.49); ORR 71%',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First BCMA CAR-T approved', 'Established manufacturing', 'PFS benefit in earlier line'],
    weaknesses: ['Inferior to Carvykti in response depth', 'Shorter DOR', 'BMS/2seventy manufacturing challenges'],
    source: 'FDA label; KarMMa trials; BMS 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'FOLFIRINOX',
    company: 'Generic regimen',
    indication: 'Pancreatic Ductal Adenocarcinoma',
    indication_specifics: '1L metastatic PDAC, fit patients',
    mechanism: 'Combination chemotherapy (5-FU/LV/irinotecan/oxaliplatin)',
    mechanism_category: 'chemotherapy',
    molecular_target: undefined,
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'PRODIGE 4/ACCORD 11: mOS 11.1 vs 6.8 mo vs gemcitabine',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Best OS in 1L PDAC', 'Proven regimen', 'Low drug cost'],
    weaknesses: ['Severe toxicity', 'Not tolerable in many patients', 'No targeted component'],
    source: 'NCCN Guidelines; PRODIGE 4 trial',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Abraxane',
    generic_name: 'nab-paclitaxel',
    company: 'BMS (ex-Celgene)',
    indication: 'Pancreatic Ductal Adenocarcinoma',
    indication_specifics: '1L metastatic PDAC + gemcitabine',
    mechanism: 'Nanoparticle albumin-bound taxane',
    mechanism_category: 'chemotherapy',
    molecular_target: undefined,
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'MPACT: mOS 8.5 vs 6.7 mo with gem/abraxane vs gem alone',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Better tolerated than FOLFIRINOX', 'Suitable for older patients', 'Well-characterized safety'],
    weaknesses: ['Inferior efficacy vs FOLFIRINOX', 'Peripheral neuropathy', 'Patent cliff'],
    source: 'FDA label; MPACT trial; BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'RAS(ON) inhibitor (MRTX1133)',
    generic_name: 'MRTX1133',
    company: 'Mirati/BMS',
    indication: 'Pancreatic Ductal Adenocarcinoma',
    indication_specifics: 'KRAS G12D-mutated PDAC',
    mechanism: 'KRAS G12D(ON) inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'KRAS G12D',
    phase: 'Phase 1/2',
    primary_endpoint: 'ORR',
    key_data: 'Phase 1: Dose-dependent tumor shrinkage in KRAS G12D+ PDAC patients',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Targets dominant KRAS mutation in PDAC (~30%)', 'First KRAS G12D inhibitor', 'Transformative potential'],
    weaknesses: ['Very early data', 'Narrow patient selection', 'Combination strategy unclear'],
    source: 'AACR 2024; NCT05737706',
    last_updated: '2024-10-01',
  },

  // ══════════════════════════════════════════════════════════
  // ACUTE MYELOID LEUKEMIA (AML)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Venclexta',
    generic_name: 'venetoclax',
    company: 'AbbVie/Roche',
    indication: 'Acute Myeloid Leukemia',
    indication_specifics: '1L AML with azacitidine in patients ineligible for intensive chemo',
    mechanism: 'BCL-2 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BCL-2',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'VIALE-A: mOS 14.7 vs 9.6 mo with ven/aza vs aza (HR 0.66)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Standard-of-care in unfit AML', 'Deepest responses without intensive chemo', 'Expanding to MDS'],
    weaknesses: ['Tumor lysis syndrome risk', 'Cytopenias', 'Resistance via BCL-2 independence'],
    source: 'FDA label; VIALE-A trial; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ivosidenib',
    generic_name: 'ivosidenib',
    company: 'Servier',
    indication: 'Acute Myeloid Leukemia',
    indication_specifics: 'IDH1-mutated AML (newly diagnosed or R/R)',
    mechanism: 'IDH1 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'IDH1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'AGILE: 1L IDH1+ AML CR/CRh 47.2% vs 14.9% with ivo/aza vs aza',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Biomarker-selected', 'Oral administration', 'Durable responses in IDH1+'],
    weaknesses: ['Small patient subset (~8% AML)', 'Differentiation syndrome risk', 'Competition from broader-acting agents'],
    source: 'FDA label; AGILE trial; Servier 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Revumenib',
    generic_name: 'revumenib',
    company: 'Syndax Pharmaceuticals',
    indication: 'Acute Myeloid Leukemia',
    indication_specifics: 'R/R KMT2A-rearranged AML',
    mechanism: 'Menin inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'Menin-KMT2A',
    phase: 'Approved',
    primary_endpoint: 'CR/CRh',
    key_data: 'AUGMENT-101: CR/CRh 21.1% in R/R KMT2A-rearranged AML; MRD negativity 78% of CR',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First menin inhibitor approved', 'Novel mechanism', 'MRD negativity achievable'],
    weaknesses: ['QTc prolongation', 'Differentiation syndrome', 'Small patient population'],
    source: 'FDA label; AUGMENT-101 trial; Syndax 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Imbruvica',
    generic_name: 'ibrutinib',
    company: 'AbbVie/Johnson & Johnson',
    indication: 'Chronic Lymphocytic Leukemia',
    indication_specifics: '1L and R/R CLL; including del(17p)',
    mechanism: 'BTK inhibitor (covalent)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'RESONATE-2: PFS NR vs 15 mo at 5 yr vs chlorambucil in 1L; ALPINE inferior to zanubrutinib',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First BTK inhibitor', 'Extensive real-world data', 'Multiple heme indications'],
    weaknesses: ['Cardiac toxicity (A-fib, HTN)', 'Off-target kinase effects', 'Losing share to 2nd-gen BTKi'],
    source: 'FDA label; RESONATE/ALPINE trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Brukinsa',
    generic_name: 'zanubrutinib',
    company: 'BeiGene',
    indication: 'Chronic Lymphocytic Leukemia',
    indication_specifics: '1L and R/R CLL/SLL',
    mechanism: 'BTK inhibitor (next-gen, selective)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ALPINE: PFS superior to ibrutinib in R/R CLL (HR 0.65); better cardiac safety',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Best-in-class safety vs ibrutinib', 'Head-to-head PFS superiority', 'Rapid share gain'],
    weaknesses: ['Not yet established in 1L fixed-duration', 'Neutropenia', 'Same resistance mechanism as ibrutinib'],
    source: 'FDA label; ALPINE trial; BeiGene 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Calquence',
    generic_name: 'acalabrutinib',
    company: 'AstraZeneca',
    indication: 'Chronic Lymphocytic Leukemia',
    indication_specifics: '1L and R/R CLL',
    mechanism: 'BTK inhibitor (2nd-gen, selective)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ELEVATE-TN: 1L PFS 87% at 4 yr with aca-obinutuzumab; ASCEND: R/R PFS superior to BR/IdR',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Strong 1L data with obinutuzumab', 'Fixed-duration potential', 'Better GI tolerability'],
    weaknesses: ['Headache common', 'Losing share to zanubrutinib', 'No head-to-head vs zanubrutinib'],
    source: 'FDA label; ELEVATE-TN/ASCEND; AZ 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // ALZHEIMER'S DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Leqembi',
    generic_name: 'lecanemab',
    company: 'Eisai/Biogen',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Early AD with confirmed amyloid pathology',
    mechanism: 'Anti-amyloid beta antibody (protofibril-selective)',
    mechanism_category: 'anti_amyloid',
    molecular_target: 'Amyloid beta (protofibrils)',
    phase: 'Approved',
    primary_endpoint: 'CDR-SB',
    key_data: 'Clarity AD: CDR-SB decline -27% vs placebo at 18 mo; 59% amyloid clearance',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First anti-amyloid with traditional approval', 'Amyloid clearance', 'IV and SC formulations'],
    weaknesses: ['ARIA-E/H risk (12.6%)', 'Modest clinical benefit debated', 'Infusion burden', 'Amyloid PET/CSF required'],
    source: 'FDA label; Clarity AD trial; Eisai 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Kisunla',
    generic_name: 'donanemab',
    company: 'Eli Lilly',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Early symptomatic AD with amyloid and tau pathology',
    mechanism: 'Anti-amyloid beta antibody (N3pG-selective)',
    mechanism_category: 'anti_amyloid',
    molecular_target: 'Amyloid beta (pyroglutamate)',
    phase: 'Approved',
    primary_endpoint: 'iADRS',
    key_data: 'TRAILBLAZER-ALZ 2: iADRS decline -35% vs placebo (low/med tau); 80% amyloid clearance → stop dosing',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Higher magnitude benefit in low/med tau', 'Treatment completion (amyloid clearance endpoint)', 'Time-limited dosing'],
    weaknesses: ['ARIA-E/H risk', 'Tau PET stratification complex', 'Amyloid PET required', 'High drug cost'],
    source: 'FDA label; TRAILBLAZER-ALZ 2; Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Remternetug',
    generic_name: 'remternetug',
    company: 'Eli Lilly',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Early AD with amyloid pathology (subcutaneous)',
    mechanism: 'Anti-amyloid beta antibody (pyroglutamate + fibril)',
    mechanism_category: 'anti_amyloid',
    molecular_target: 'Amyloid beta',
    phase: 'Phase 3',
    primary_endpoint: 'CDR-SB',
    key_data: 'Phase 2: >80% amyloid clearance by 12 weeks; fastest amyloid removal observed',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['SC formulation', 'Fastest amyloid clearance', 'Could enable shortest treatment duration'],
    weaknesses: ['ARIA risk may be higher with rapid clearance', 'Phase 3 not yet reported', 'Behind donanemab in development'],
    source: 'NCT05463731; Eli Lilly 2024',
    last_updated: '2024-10-01',
  },
  {
    asset_name: 'Aricept',
    generic_name: 'donepezil',
    company: 'Eisai/Pfizer (generic)',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Mild, moderate, and severe AD (cholinesterase inhibitor)',
    mechanism: 'Acetylcholinesterase inhibitor',
    mechanism_category: 'cholinesterase_inhibitor',
    molecular_target: 'Acetylcholinesterase',
    phase: 'Approved',
    primary_endpoint: 'ADAS-Cog',
    key_data: 'Pivotal trials: ADAS-Cog improvement ~2-3 points vs placebo at 24 weeks; standard of care for 25+ years',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Established standard of care', 'Once-daily oral dosing', 'Generic availability', 'All severity stages'],
    weaknesses: ['Symptomatic only (not disease-modifying)', 'GI side effects', 'Modest cognitive benefit', 'Effect wanes over time'],
    source: 'FDA label; Eisai prescribing information',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Simufilam',
    generic_name: 'simufilam',
    company: 'Cassava Sciences',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Mild-to-moderate AD',
    mechanism: 'Filamin A protein modulator (restores receptor signaling)',
    mechanism_category: 'protein_modulator',
    molecular_target: 'Filamin A',
    phase: 'Phase 3',
    primary_endpoint: 'ADAS-Cog11',
    key_data: 'RETHINK-ALZ: Phase 3 ongoing; open-label showed sustained ADAS-Cog improvement over 12 months; oral BID dosing',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Oral administration (no infusion)', 'Non-amyloid mechanism', 'Low cost potential if approved'],
    weaknesses: ['Data integrity controversies', 'SEC investigation history', 'Phase 3 results pending', 'Novel unvalidated target'],
    source: 'NCT04994483; Cassava Sciences 2024',
    last_updated: '2024-12-01',
  },

  // ══════════════════════════════════════════════════════════
  // PARKINSON'S DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Prasinezumab',
    generic_name: 'prasinezumab',
    company: 'Roche/Prothena',
    indication: "Parkinson's Disease",
    indication_specifics: 'Early PD (disease modification)',
    mechanism: 'Anti-alpha-synuclein antibody',
    mechanism_category: 'anti_alpha_synuclein',
    molecular_target: 'Alpha-synuclein',
    phase: 'Phase 2/3',
    primary_endpoint: 'MDS-UPDRS Part III',
    key_data: 'PADOVA: 28% reduction in motor progression in rapidly progressing subgroup; PASADENA: signals in motor function',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First anti-synuclein to show motor benefit', 'Disease modification potential', 'Strong Roche partnership'],
    weaknesses: ['Missed primary endpoint in PASADENA', 'Subgroup-driven benefit', 'Long development timeline'],
    source: 'PADOVA (NCT04777331); Roche/Prothena 2024',
    last_updated: '2024-12-01',
  },

  // ══════════════════════════════════════════════════════════
  // RHEUMATOID ARTHRITIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Humira',
    generic_name: 'adalimumab',
    company: 'AbbVie',
    indication: 'Rheumatoid Arthritis',
    indication_specifics: 'Moderate-to-severe RA after csDMARD failure',
    mechanism: 'Anti-TNF monoclonal antibody',
    mechanism_category: 'anti_tnf',
    molecular_target: 'TNF-alpha',
    phase: 'Approved',
    primary_endpoint: 'ACR20',
    key_data: 'ARMADA/PREMIER: ACR20 67-73% at 6 months; > 15 years of real-world data',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Best-selling drug in history', 'Extensive evidence base', 'Multiple autoimmune indications'],
    weaknesses: ['Biosimilar erosion (10+ biosimilars launched)', 'Class infection risk', 'Revenue declining rapidly'],
    source: 'FDA label; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rinvoq',
    generic_name: 'upadacitinib',
    company: 'AbbVie',
    indication: 'Rheumatoid Arthritis',
    indication_specifics: 'Moderate-to-severe RA after csDMARD inadequate response',
    mechanism: 'JAK1 inhibitor (selective)',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1',
    phase: 'Approved',
    primary_endpoint: 'ACR20',
    key_data: 'SELECT-COMPARE: ACR50 45.2% vs 29.1% vs Humira at 12 wk; radiographic superiority',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Superior to adalimumab in ACR50', 'Oral convenience', 'Multiple autoimmune indications'],
    weaknesses: ['JAK class boxed warning (CV, thrombotic events)', 'FDA label restrictions post-ORAL Surveillance', 'Regulatory headwinds'],
    source: 'FDA label; SELECT trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Olokizumab',
    generic_name: 'olokizumab',
    company: 'R-Pharm/UCB',
    indication: 'Rheumatoid Arthritis',
    indication_specifics: 'Moderate-to-severe RA after csDMARD inadequate response',
    mechanism: 'Anti-IL-6 antibody',
    mechanism_category: 'anti_il6',
    molecular_target: 'IL-6',
    phase: 'Phase 3',
    primary_endpoint: 'ACR20',
    key_data: 'CREDO trials: ACR20 non-inferior to tocilizumab; monthly SC dosing',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Monthly SC dosing convenience', 'Non-inferior to tocilizumab', 'Direct IL-6 targeting'],
    weaknesses: ['Crowded RA market', 'JAK inhibitor competition', 'Not clearly differentiated from Actemra'],
    source: 'CREDO trials; R-Pharm 2024',
    last_updated: '2024-10-01',
  },

  // ══════════════════════════════════════════════════════════
  // ULCERATIVE COLITIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Entyvio',
    generic_name: 'vedolizumab',
    company: 'Takeda',
    indication: 'Ulcerative Colitis',
    indication_specifics: 'Moderate-to-severe UC after conventional therapy failure',
    mechanism: 'Anti-alpha4beta7 integrin antibody',
    mechanism_category: 'anti_integrin',
    molecular_target: 'Alpha4beta7',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission',
    key_data: 'GEMINI 1: Clinical remission 41.8% vs 15.9% at 52 wk; gut-selective mechanism',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Gut-selective (safety advantage)', '$5B+ blockbuster', 'SC formulation available'],
    weaknesses: ['Slower onset than anti-TNF', 'Biosimilar competition emerging', 'Not effective in all patients'],
    source: 'FDA label; GEMINI trials; Takeda 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Skyrizi',
    generic_name: 'risankizumab',
    company: 'AbbVie',
    indication: 'Ulcerative Colitis',
    indication_specifics: 'Moderate-to-severe UC after conventional therapy failure',
    mechanism: 'Anti-IL-23 (p19) antibody',
    mechanism_category: 'anti_il23',
    molecular_target: 'IL-23 (p19)',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission',
    key_data: 'COMMAND: Clinical remission 36.6% vs 12.5% at 52 wk; strong endoscopic response',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Clean safety profile', 'Growing IL-23 class evidence', 'Dual IBD indication (UC + Crohn\'s)'],
    weaknesses: ['Later entrant vs Stelara/Entyvio', 'SC only', 'Competitive with guselkumab for share'],
    source: 'FDA label; COMMAND trial; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tremfya',
    generic_name: 'guselkumab',
    company: 'Johnson & Johnson',
    indication: 'Ulcerative Colitis',
    indication_specifics: 'Moderate-to-severe UC (Phase 3 ongoing)',
    mechanism: 'Anti-IL-23 (p19) antibody',
    mechanism_category: 'anti_il23',
    molecular_target: 'IL-23 (p19)',
    phase: 'Phase 3',
    primary_endpoint: 'Clinical remission',
    key_data: 'QUASAR: Phase 3 results pending; strong Phase 2 UC data; approved for psoriasis',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong psoriasis franchise', 'IL-23 class momentum', 'Dual targeting with CD64 binding'],
    weaknesses: ['Behind Skyrizi in IBD development', 'Phase 3 results pending', 'Crowded class'],
    source: 'QUASAR trials; J&J 2024',
    last_updated: '2024-10-01',
  },

  // ══════════════════════════════════════════════════════════
  // ATOPIC DERMATITIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Dupixent',
    generic_name: 'dupilumab',
    company: 'Sanofi/Regeneron',
    indication: 'Atopic Dermatitis',
    indication_specifics: 'Moderate-to-severe AD in adults and children >= 6 months',
    mechanism: 'Anti-IL-4Ra monoclonal antibody (blocks IL-4 and IL-13)',
    mechanism_category: 'anti_il4',
    molecular_target: 'IL-4Ra',
    phase: 'Approved',
    primary_endpoint: 'EASI-75',
    key_data: 'LIBERTY AD: EASI-75 51% vs 15% at 16 wk; $12B+ blockbuster across indications',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First-in-class biologic in AD', 'Pediatric approval', '$12B+ revenue across indications'],
    weaknesses: ['Injection site reactions', 'Conjunctivitis', 'JAK inhibitor competition'],
    source: 'FDA label; LIBERTY AD trials; Sanofi 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Adbry',
    generic_name: 'tralokinumab',
    company: 'LEO Pharma',
    indication: 'Atopic Dermatitis',
    indication_specifics: 'Moderate-to-severe AD in adults',
    mechanism: 'Anti-IL-13 monoclonal antibody',
    mechanism_category: 'anti_il13',
    molecular_target: 'IL-13',
    phase: 'Approved',
    primary_endpoint: 'EASI-75',
    key_data: 'ECZTRA 1/2: EASI-75 25-33% monotherapy at 16 wk; improved with TCS',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Selective IL-13 targeting', 'Good safety profile', 'Alternative for Dupixent non-responders'],
    weaknesses: ['Lower efficacy than Dupixent', 'Limited market share', 'No pediatric indication yet'],
    source: 'FDA label; ECZTRA trials; LEO Pharma 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cibinqo',
    generic_name: 'abrocitinib',
    company: 'Pfizer',
    indication: 'Atopic Dermatitis',
    indication_specifics: 'Moderate-to-severe AD in adults after other systemics',
    mechanism: 'JAK1 inhibitor (oral)',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1',
    phase: 'Approved',
    primary_endpoint: 'IGA 0/1',
    key_data: 'JADE COMPARE: 200mg IGA 0/1 48.4% vs 36.5% dupilumab vs 14.0% placebo at 12 wk',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Oral convenience', 'Rapid onset of action', 'Numerical superiority vs Dupixent at high dose'],
    weaknesses: ['JAK boxed warning', 'Restricted to after other systemics', 'Herpes zoster risk'],
    source: 'FDA label; JADE trials; Pfizer 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // SPINAL MUSCULAR ATROPHY (SMA) — Rare Disease
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Zolgensma',
    generic_name: 'onasemnogene abeparvovec',
    company: 'Novartis',
    indication: 'Spinal Muscular Atrophy',
    indication_specifics: 'SMA Type 1 in patients < 2 years',
    mechanism: 'AAV9 gene therapy (SMN1 gene replacement)',
    mechanism_category: 'gene_therapy',
    molecular_target: 'SMN1',
    phase: 'Approved',
    primary_endpoint: 'Survival/motor milestones',
    key_data: 'STR1VE: 91% survived event-free at 14 mo; 59% sitting independently',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['One-time curative therapy', 'Dramatic motor milestone achievement', 'Transformative for SMA Type 1'],
    weaknesses: ['$2.1M price point', 'Hepatotoxicity (TMA)', 'Age/weight restrictions', 'Immunogenicity to AAV9'],
    source: 'FDA label; STR1VE trial; Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Spinraza',
    generic_name: 'nusinersen',
    company: 'Biogen',
    indication: 'Spinal Muscular Atrophy',
    indication_specifics: 'All types of SMA (intrathecal administration)',
    mechanism: 'Antisense oligonucleotide (SMN2 splicing modifier)',
    mechanism_category: 'antisense_oligonucleotide',
    molecular_target: 'SMN2',
    phase: 'Approved',
    primary_endpoint: 'Motor function (HFMSE)',
    key_data: 'ENDEAR: 51% motor milestone responders vs 0% in SMA Type 1; NURTURE: presymptomatic benefit',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First SMA therapy approved', 'Broadest age/type coverage', 'Long-term safety data'],
    weaknesses: ['Intrathecal administration every 4 months', 'Declining revenue with Zolgensma/Evrysdi competition', 'Access challenges for older patients'],
    source: 'FDA label; ENDEAR/NURTURE trials; Biogen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Evrysdi',
    generic_name: 'risdiplam',
    company: 'Roche/Genentech',
    indication: 'Spinal Muscular Atrophy',
    indication_specifics: 'All types of SMA, age >= 2 months (oral)',
    mechanism: 'Small molecule SMN2 splicing modifier',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'SMN2',
    phase: 'Approved',
    primary_endpoint: 'Motor function',
    key_data: 'FIREFISH: Type 1 sitting 29% at 12 mo; SUNFISH: Type 2/3 MFM-32 improvement',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Oral (liquid) at-home dosing', 'No age restriction above 2 months', 'CNS + peripheral distribution'],
    weaknesses: ['Requires continuous daily dosing', 'Lower efficacy ceiling than Zolgensma in Type 1', 'Retinal toxicity signal in animals'],
    source: 'FDA label; FIREFISH/SUNFISH trials; Roche 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // MELANOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Opdivo + Yervoy',
    generic_name: 'nivolumab + ipilimumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Melanoma',
    indication_specifics: '1L unresectable or metastatic melanoma',
    mechanism: 'PD-1 + CTLA-4 dual checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_combo',
    molecular_target: 'PD-1/CTLA-4',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate-067: 5-yr OS 52% with nivo+ipi vs 44% nivo vs 26% ipi; mOS 72.1 mo',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Highest long-term survival in melanoma', 'Durable responses', 'Practice-changing IO-IO combination'],
    weaknesses: ['Grade 3/4 toxicity ~59%', 'Complex dosing schedule', 'High cost of combination'],
    source: 'FDA label; CheckMate-067 trial; BMS 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Melanoma',
    indication_specifics: '1L unresectable/metastatic melanoma; adjuvant after resection',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'KEYNOTE-006: 5-yr OS 38.7% vs 31.0% ipilimumab; KEYNOTE-054: adjuvant RFS HR 0.57',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Broad melanoma label (1L, adjuvant, neoadjuvant)', 'Better tolerated than nivo+ipi', 'Extensive real-world data'],
    weaknesses: ['Lower long-term OS vs nivo+ipi combination', 'LOE approaching 2028', 'Monotherapy limitations in PD-L1 low'],
    source: 'FDA label; KEYNOTE-006/054 trials; Merck 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tafinlar + Mekinist',
    generic_name: 'dabrafenib + trametinib',
    company: 'Novartis',
    indication: 'Melanoma',
    indication_specifics: 'BRAF V600E/K-mutated unresectable or metastatic melanoma',
    mechanism: 'BRAF + MEK inhibitor combination',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BRAF/MEK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'COMBI-d/v: PFS 11-12 mo; 5-yr OS 34%; adjuvant COMBI-AD: RFS HR 0.51',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Rapid response in BRAF+ patients', 'Oral combination', 'Adjuvant indication'],
    weaknesses: ['Limited to BRAF-mutated (~50% of melanoma)', 'Resistance develops within 12 months', 'Pyrexia management burden'],
    source: 'FDA label; COMBI trials; Novartis 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Opdualag',
    generic_name: 'nivolumab + relatlimab',
    company: 'Bristol-Myers Squibb',
    indication: 'Melanoma',
    indication_specifics: '1L unresectable or metastatic melanoma',
    mechanism: 'PD-1 + LAG-3 dual checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_combo',
    molecular_target: 'PD-1/LAG-3',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'RELATIVITY-047: PFS 10.1 vs 4.6 mo vs nivolumab alone (HR 0.75)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First LAG-3 blocking antibody approved', 'Better tolerability than nivo+ipi', 'Novel checkpoint combination'],
    weaknesses: ['No OS benefit demonstrated yet', 'Inferior PFS vs nivo+ipi', 'Limited differentiation from anti-PD-1 monotherapy'],
    source: 'FDA label; RELATIVITY-047 trial; BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lifileucel',
    generic_name: 'lifileucel',
    company: 'Iovance Biotherapeutics',
    indication: 'Melanoma',
    indication_specifics: 'Unresectable or metastatic melanoma after PD-1 and BRAF+MEK (if BRAF V600+)',
    mechanism: 'Tumor-infiltrating lymphocyte (TIL) cell therapy',
    mechanism_category: 'cell_therapy',
    molecular_target: 'Tumor antigens (polyclonal TIL)',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'C-144-01: ORR 31.5% in heavily pretreated melanoma; CR rate 4.5%; median DOR not reached',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First TIL therapy approved', 'Active after checkpoint failure', 'Durable responses in responders'],
    weaknesses: ['Complex manufacturing (22-day vein-to-vein)', 'Lymphodepletion required', 'Limited manufacturing capacity'],
    source: 'FDA label; C-144-01 trial; Iovance 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // RENAL CELL CARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Keytruda + Lenvima',
    generic_name: 'pembrolizumab + lenvatinib',
    company: 'Merck/Eisai',
    indication: 'Renal Cell Carcinoma',
    indication_specifics: '1L advanced RCC, all IMDC risk groups',
    mechanism: 'PD-1 inhibitor + multi-kinase TKI (VEGFR/FGFR/RET)',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1/VEGFR',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'KEYNOTE-581/CLEAR: PFS 23.9 vs 9.2 mo vs sunitinib (HR 0.39); OS HR 0.66',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Best PFS in 1L RCC', 'OS benefit confirmed', 'Active across all IMDC risk groups'],
    weaknesses: ['High Grade 3+ toxicity rate (72%)', 'Dual cost burden', 'Dose reductions common for lenvatinib'],
    source: 'FDA label; CLEAR trial; Merck/Eisai 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Opdivo + Yervoy',
    generic_name: 'nivolumab + ipilimumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Renal Cell Carcinoma',
    indication_specifics: '1L intermediate/poor-risk advanced RCC',
    mechanism: 'PD-1 + CTLA-4 dual checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_combo',
    molecular_target: 'PD-1/CTLA-4',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate-214: 5-yr OS 43% vs 31% sunitinib in int/poor risk (HR 0.68); CR rate 12%',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Durable complete responses', 'IO-IO paradigm', 'Long-term OS benefit in int/poor risk'],
    weaknesses: ['Less effective in favorable-risk', 'High immune-related AE rate', 'Limited time on ipilimumab (4 cycles)'],
    source: 'FDA label; CheckMate-214 trial; BMS 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cabometyx + Opdivo',
    generic_name: 'cabozantinib + nivolumab',
    company: 'Exelixis/BMS',
    indication: 'Renal Cell Carcinoma',
    indication_specifics: '1L advanced RCC, all IMDC risk groups',
    mechanism: 'Multi-TKI (VEGFR/MET/AXL) + PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'VEGFR/MET/AXL/PD-1',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'CheckMate-9ER: PFS 16.6 vs 8.3 mo vs sunitinib (HR 0.51); OS HR 0.70',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong PFS and OS benefit', 'Active across all risk groups', 'MET/AXL coverage provides differentiation'],
    weaknesses: ['High AE rate with combination', 'Dose reductions common', 'Three-drug cost'],
    source: 'FDA label; CheckMate-9ER trial; Exelixis/BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Inlyta',
    generic_name: 'axitinib',
    company: 'Pfizer',
    indication: 'Renal Cell Carcinoma',
    indication_specifics: '2L+ advanced RCC after one prior systemic therapy; 1L with pembrolizumab',
    mechanism: 'Selective VEGFR TKI',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'VEGFR1/2/3',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'KEYNOTE-426 (with pembro): PFS 15.4 vs 11.1 mo vs sunitinib (HR 0.68); OS HR 0.68',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Established combination partner', 'Well-known safety profile', 'Available generic pathway'],
    weaknesses: ['Hypertension management', 'Less differentiated as monotherapy', 'Losing share to cabo+nivo and len+pembro'],
    source: 'FDA label; KEYNOTE-426 trial; Pfizer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Welireg',
    generic_name: 'belzutifan',
    company: 'Merck',
    indication: 'Renal Cell Carcinoma',
    indication_specifics: 'VHL disease-associated RCC; 2L+ advanced RCC after anti-PD-1 and TKI',
    mechanism: 'HIF-2alpha inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'HIF-2alpha',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'LITESPARK-005: PFS 5.6 vs 5.6 mo vs everolimus but OS HR 0.88; VHL ORR 64%',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First-in-class HIF-2a inhibitor', 'VHL niche with high ORR', 'Novel mechanism orthogonal to IO/TKI'],
    weaknesses: ['Modest benefit in broad RCC', 'Anemia management', 'Narrow positioning'],
    source: 'FDA label; LITESPARK trials; Merck 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HEPATOCELLULAR CARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Tecentriq + Avastin',
    generic_name: 'atezolizumab + bevacizumab',
    company: 'Roche/Genentech',
    indication: 'Hepatocellular Carcinoma',
    indication_specifics: '1L unresectable HCC not previously treated with systemic therapy',
    mechanism: 'PD-L1 inhibitor + anti-VEGF antibody',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1/VEGF',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'IMbrave150: OS 19.2 vs 13.4 mo vs sorafenib (HR 0.66); PFS HR 0.65',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First IO regimen in 1L HCC', 'Practice-changing OS benefit', 'Well-established safety'],
    weaknesses: ['Bleeding risk with bevacizumab (variceal screening required)', 'IV administration', 'Not for Child-Pugh B/C'],
    source: 'FDA label; IMbrave150 trial; Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Imfinzi + Imjudo',
    generic_name: 'durvalumab + tremelimumab',
    company: 'AstraZeneca',
    indication: 'Hepatocellular Carcinoma',
    indication_specifics: '1L unresectable HCC',
    mechanism: 'PD-L1 + CTLA-4 dual checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_combo',
    molecular_target: 'PD-L1/CTLA-4',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'HIMALAYA: STRIDE regimen mOS 16.4 vs 13.8 mo vs sorafenib (HR 0.78); 3-yr OS 30.7%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Single priming dose of treme reduces toxicity', 'No anti-VEGF needed (avoids bleeding risk)', 'STRIDE dosing innovation'],
    weaknesses: ['Numerically inferior to atezo+bev in cross-trial comparison', 'Limited uptake vs IMbrave regimen', 'Hepatic toxicity risk'],
    source: 'FDA label; HIMALAYA trial; AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nexavar',
    generic_name: 'sorafenib',
    company: 'Bayer',
    indication: 'Hepatocellular Carcinoma',
    indication_specifics: 'Unresectable HCC (historical standard; now 2L or IO-ineligible)',
    mechanism: 'Multi-kinase inhibitor (VEGFR, RAF, PDGFR)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'VEGFR/RAF/PDGFR',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'SHARP: mOS 10.7 vs 7.9 mo vs placebo (HR 0.69); first systemic therapy for HCC',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First systemic therapy for HCC', 'Extensive safety data', 'Generic availability lowers cost'],
    weaknesses: ['Displaced to 2L+ by IO combinations', 'Hand-foot syndrome', 'Modest efficacy by modern standards'],
    source: 'FDA label; SHARP trial; Bayer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lenvima',
    generic_name: 'lenvatinib',
    company: 'Eisai',
    indication: 'Hepatocellular Carcinoma',
    indication_specifics: '1L unresectable HCC',
    mechanism: 'Multi-kinase inhibitor (VEGFR1-3, FGFR1-4, PDGFRa, RET, KIT)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'VEGFR/FGFR/RET',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'REFLECT: mOS 13.6 vs 12.3 mo (non-inferior to sorafenib); ORR 24.1% vs 9.2%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Higher ORR than sorafenib', 'Alternative for IO-ineligible patients', 'Combination studies ongoing'],
    weaknesses: ['No superiority over sorafenib in OS', 'Hypertension/proteinuria', 'Displaced by IO combinations'],
    source: 'FDA label; REFLECT trial; Eisai 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Camrelizumab + Rivoceranib',
    generic_name: 'camrelizumab + rivoceranib',
    company: 'Hengrui/Elevar Therapeutics',
    indication: 'Hepatocellular Carcinoma',
    indication_specifics: '1L unresectable or metastatic HCC',
    mechanism: 'PD-1 inhibitor + VEGFR2 TKI',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1/VEGFR2',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CARES-310: mOS 22.1 vs 15.2 mo vs sorafenib (HR 0.62); PFS 5.6 vs 3.7 mo (HR 0.52)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong OS benefit vs sorafenib', 'All-oral TKI component', 'Competitive with IMbrave regimen'],
    weaknesses: ['Limited US uptake so far', 'Reactive capillary hemangiomas', 'Hypertension management'],
    source: 'FDA label; CARES-310 trial; Elevar 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Opdivo + Chemo',
    generic_name: 'nivolumab + chemotherapy',
    company: 'Bristol-Myers Squibb',
    indication: 'Gastric/Gastroesophageal Junction Cancer',
    indication_specifics: '1L HER2-negative advanced gastric/GEJ/esophageal adenocarcinoma',
    mechanism: 'PD-1 inhibitor + chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate-649: mOS 13.8 vs 11.6 mo with nivo+chemo vs chemo (HR 0.80); PD-L1 CPS>=5 OS HR 0.71',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Standard-of-care in 1L gastric', 'Greater benefit in CPS>=5', 'Broad global label'],
    weaknesses: ['Modest OS gain in all-comers', 'Chemotherapy backbone toxicity', 'PD-L1 testing required for optimal selection'],
    source: 'FDA label; CheckMate-649 trial; BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda + Chemo',
    generic_name: 'pembrolizumab + chemotherapy',
    company: 'Merck',
    indication: 'Gastric/Gastroesophageal Junction Cancer',
    indication_specifics: '1L HER2-negative locally advanced/metastatic gastric/GEJ adenocarcinoma',
    mechanism: 'PD-1 inhibitor + chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-859: mOS 12.9 vs 11.5 mo vs chemo (HR 0.78); PD-L1 CPS>=10 OS HR 0.65',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Broad label with pembro franchise', 'Strong benefit in PD-L1 high', 'Familiar safety profile'],
    weaknesses: ['Incremental OS gain in unselected population', 'Late entry vs CheckMate-649', 'Chemotherapy combination burden'],
    source: 'FDA label; KEYNOTE-859 trial; Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Enhertu',
    generic_name: 'trastuzumab deruxtecan',
    company: 'Daiichi Sankyo/AstraZeneca',
    indication: 'Gastric/Gastroesophageal Junction Cancer',
    indication_specifics: 'HER2+ locally advanced or metastatic gastric/GEJ after trastuzumab',
    mechanism: 'ADC (HER2)',
    mechanism_category: 'adc',
    molecular_target: 'HER2',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'DESTINY-Gastric01: ORR 51.3% vs 14.3% chemo; OS 12.5 vs 8.4 mo (HR 0.59) in 3L+ HER2+',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Superior ORR in HER2+ gastric', 'OS benefit in post-trastuzumab setting', 'ADC platform strength'],
    weaknesses: ['Limited to HER2+ (~20%)', 'ILD/pneumonitis risk', 'IV administration every 3 weeks'],
    source: 'FDA label; DESTINY-Gastric01 trial; Daiichi Sankyo 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Herceptin',
    generic_name: 'trastuzumab',
    company: 'Roche/Genentech',
    indication: 'Gastric/Gastroesophageal Junction Cancer',
    indication_specifics: '1L HER2-overexpressing metastatic gastric/GEJ + chemo',
    mechanism: 'Anti-HER2 monoclonal antibody',
    mechanism_category: 'anti_her2',
    molecular_target: 'HER2',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'ToGA: mOS 13.8 vs 11.1 mo with H+chemo vs chemo (HR 0.74) in HER2+ gastric',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Established standard in HER2+ gastric', 'Extensive global experience', 'Biosimilar cost reduction'],
    weaknesses: ['Limited to HER2+ population', 'Cardiac monitoring needed', 'Biosimilar commoditization'],
    source: 'FDA label; ToGA trial; Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vyloy',
    generic_name: 'zolbetuximab',
    company: 'Astellas',
    indication: 'Gastric/Gastroesophageal Junction Cancer',
    indication_specifics: '1L CLDN18.2+, HER2- locally advanced/metastatic gastric/GEJ adenocarcinoma',
    mechanism: 'Anti-Claudin 18.2 monoclonal antibody',
    mechanism_category: 'anti_claudin',
    molecular_target: 'Claudin 18.2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'SPOTLIGHT: PFS 10.6 vs 8.7 mo (HR 0.75); GLOW: PFS 8.2 vs 6.8 mo (HR 0.69) + chemo vs chemo',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First-in-class Claudin 18.2 target', 'Novel biomarker-selected approach', 'Moderate PFS benefit'],
    weaknesses: ['Nausea/vomiting common', 'CLDN18.2 IHC testing infrastructure needed', 'Modest absolute benefit'],
    source: 'FDA label; SPOTLIGHT/GLOW trials; Astellas 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // UROTHELIAL CARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Urothelial Carcinoma',
    indication_specifics: '2L+ locally advanced/metastatic UC post-platinum; 1L cisplatin-ineligible PD-L1+',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-045: mOS 10.3 vs 7.4 mo vs chemo (HR 0.73); ORR 21.1% in 2L UC',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Established 2L UC standard', 'Durable responses', 'Expanding to perioperative settings'],
    weaknesses: ['Modest ORR as monotherapy', 'PD-L1 selection needed in 1L cisplatin-ineligible', 'Competition from enfortumab combos'],
    source: 'FDA label; KEYNOTE-045 trial; Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Padcev',
    generic_name: 'enfortumab vedotin',
    company: 'Astellas/Seagen (Pfizer)',
    indication: 'Urothelial Carcinoma',
    indication_specifics: '1L locally advanced/metastatic UC with pembrolizumab; 2L+ post-platinum and IO',
    mechanism: 'ADC (Nectin-4)',
    mechanism_category: 'adc',
    molecular_target: 'Nectin-4',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'EV-302: 1L EV+pembro mOS 31.5 vs 16.1 mo vs chemo (HR 0.47); PFS HR 0.45',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Paradigm-shifting 1L OS benefit', 'Active regardless of PD-L1', 'Chemo-free regimen'],
    weaknesses: ['Skin toxicity (rash, SJS/TEN risk)', 'Peripheral neuropathy', 'Hyperglycemia management'],
    source: 'FDA label; EV-302/EV-301 trials; Astellas/Pfizer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Imfinzi',
    generic_name: 'durvalumab',
    company: 'AstraZeneca',
    indication: 'Urothelial Carcinoma',
    indication_specifics: 'Unresectable Stage III UC maintenance after CRT; locally advanced/metastatic UC',
    mechanism: 'PD-L1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Approved',
    primary_endpoint: 'DFS',
    key_data: 'NIAGARA: perioperative durvalumab + chemo EFS HR 0.68 vs chemo in MIBC',
    line_of_therapy: 'neoadjuvant',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Perioperative bladder cancer label', 'NIAGARA paradigm shift', 'Expanding from NSCLC to UC'],
    weaknesses: ['Competitive with pembro perioperative data', 'EFS endpoint debate', 'Long-term data maturing'],
    source: 'FDA label; NIAGARA trial; AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Balversa',
    generic_name: 'erdafitinib',
    company: 'Johnson & Johnson',
    indication: 'Urothelial Carcinoma',
    indication_specifics: 'FGFR3/FGFR2 altered locally advanced/metastatic UC',
    mechanism: 'Pan-FGFR inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'FGFR1-4',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'THOR: mOS 12.1 vs 7.8 mo vs chemo (HR 0.64) in FGFR-altered UC post-IO',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First targeted therapy in UC with OS benefit', 'Oral administration', 'Biomarker-selected high response'],
    weaknesses: ['FGFR alterations in ~20% of UC', 'Hyperphosphatemia management', 'Ocular toxicity (central serous retinopathy)'],
    source: 'FDA label; THOR trial; J&J 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HEAD AND NECK SQUAMOUS CELL CARCINOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Head and Neck Squamous Cell Carcinoma',
    indication_specifics: '1L R/M HNSCC + chemo or monotherapy (PD-L1 CPS >= 1)',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-048: 1L pembro+chemo mOS 13.0 vs 10.7 mo (HR 0.77); mono CPS>=20 mOS 14.9 mo',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Standard-of-care in 1L R/M HNSCC', 'Strong benefit in PD-L1 CPS>=20', 'Monotherapy option for high expressors'],
    weaknesses: ['Modest gain in CPS 1-19', 'Chemotherapy backbone needed for most patients', 'Resistance mechanisms common'],
    source: 'FDA label; KEYNOTE-048 trial; Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Opdivo',
    generic_name: 'nivolumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Head and Neck Squamous Cell Carcinoma',
    indication_specifics: '2L+ R/M HNSCC after platinum-based chemotherapy',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate-141: mOS 7.5 vs 5.1 mo vs investigator choice (HR 0.70) in 2L HNSCC',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Established 2L standard before IO moved to 1L', 'No biomarker required', 'Durable tail on OS curve'],
    weaknesses: ['Largely displaced by Keytruda in 1L', '2L setting shrinking', 'Low ORR (~13%)'],
    source: 'FDA label; CheckMate-141 trial; BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Erbitux',
    generic_name: 'cetuximab',
    company: 'Eli Lilly',
    indication: 'Head and Neck Squamous Cell Carcinoma',
    indication_specifics: 'R/M HNSCC with platinum/5-FU or radiation; monotherapy 2L+',
    mechanism: 'Anti-EGFR monoclonal antibody',
    mechanism_category: 'anti_egfr',
    molecular_target: 'EGFR',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'EXTREME: mOS 10.1 vs 7.4 mo with cetuximab+chemo vs chemo (HR 0.80)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Long-established efficacy', 'Concurrent chemoradiation partner', 'Biomarker-independent in HNSCC'],
    weaknesses: ['Infusion reactions', 'Acneiform rash', 'Displaced by IO in R/M setting'],
    source: 'FDA label; EXTREME trial; Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Libtayo',
    generic_name: 'cemiplimab',
    company: 'Regeneron/Sanofi',
    indication: 'Head and Neck Squamous Cell Carcinoma',
    indication_specifics: '1L advanced/metastatic CSCC; expanding into HNSCC',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 3',
    primary_endpoint: 'OS',
    key_data: 'Phase 2 CSCC: ORR 47% in advanced CSCC; HNSCC Phase 3 combinations ongoing',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong CSCC franchise', 'Differentiated combination strategies', 'Head and neck expertise'],
    weaknesses: ['Behind Keytruda/Opdivo in HNSCC', 'Phase 3 data pending', 'Crowded anti-PD-1 space'],
    source: 'NCT04590963; Regeneron 2024',
    last_updated: '2024-12-01',
  },

  // ══════════════════════════════════════════════════════════
  // SMALL CELL LUNG CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Tecentriq',
    generic_name: 'atezolizumab',
    company: 'Roche/Genentech',
    indication: 'Small Cell Lung Cancer',
    indication_specifics: '1L extensive-stage SCLC with carboplatin/etoposide',
    mechanism: 'PD-L1 inhibitor + chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'IMpower133: mOS 12.3 vs 10.3 mo with atezo+chemo vs chemo (HR 0.70); 5-yr OS 12%',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First IO approved in ES-SCLC', 'Meaningful OS improvement', 'Established 1L standard'],
    weaknesses: ['Modest absolute OS benefit (~2 months)', 'Most patients relapse within 12 months', 'No biomarker for patient selection'],
    source: 'FDA label; IMpower133 trial; Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Imfinzi',
    generic_name: 'durvalumab',
    company: 'AstraZeneca',
    indication: 'Small Cell Lung Cancer',
    indication_specifics: '1L extensive-stage SCLC with etoposide + platinum',
    mechanism: 'PD-L1 inhibitor + chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CASPIAN: mOS 13.0 vs 10.3 mo with durva+chemo vs chemo (HR 0.73)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Comparable efficacy to atezolizumab', 'Strong CASPIAN data', 'Flexible platinum backbone'],
    weaknesses: ['Limited differentiation from Tecentriq', 'Same modest absolute benefit', 'Combination with tremelimumab did not add benefit'],
    source: 'FDA label; CASPIAN trial; AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zepzelca',
    generic_name: 'lurbinectedin',
    company: 'Jazz Pharmaceuticals',
    indication: 'Small Cell Lung Cancer',
    indication_specifics: '2L+ metastatic SCLC with disease progression on or after platinum-based chemo',
    mechanism: 'RNA polymerase II inhibitor (selective oncogenic transcription inhibitor)',
    mechanism_category: 'chemotherapy',
    molecular_target: 'RNA Pol II',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'Phase 2 basket: ORR 35.2% in 2L SCLC; median DOR 5.3 mo; mPFS 3.5 mo',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Only approved 2L SCLC monotherapy besides topotecan', 'Better tolerated than topotecan', 'Novel mechanism'],
    weaknesses: ['Accelerated approval (confirmatory ongoing)', 'Moderate ORR', 'Myelosuppression'],
    source: 'FDA label; Phase 2 basket trial; Jazz Pharma 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tarlatamab',
    generic_name: 'tarlatamab',
    company: 'Amgen',
    indication: 'Small Cell Lung Cancer',
    indication_specifics: '2L+ ES-SCLC after prior platinum-based chemo',
    mechanism: 'DLL3xCD3 bispecific T-cell engager (BiTE)',
    mechanism_category: 'bispecific',
    molecular_target: 'DLL3/CD3',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'DeLLphi-301: ORR 40% at 10mg; mDOR 9.7 mo; mPFS 4.9 mo in 2L+ SCLC',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First DLL3-targeted therapy', 'High ORR for SCLC 2L+', 'Durable responses', 'Moving to 1L combinations'],
    weaknesses: ['CRS risk (1% Grade 3+)', 'ICANS/neurologic events', 'Step-up dosing required'],
    source: 'FDA label; DeLLphi-301 trial; Amgen 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // OVARIAN CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Lynparza',
    generic_name: 'olaparib',
    company: 'AstraZeneca/Merck',
    indication: 'Ovarian Cancer',
    indication_specifics: '1L maintenance in BRCA-mutated advanced ovarian cancer; 2L+ maintenance post-platinum',
    mechanism: 'PARP inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'PARP1/2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'SOLO-1: 1L BRCA+ maintenance PFS 56.0 vs 13.8 mo (HR 0.33); 5-yr PFS rate 48.3%',
    line_of_therapy: 'maintenance',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Standard-of-care in BRCA+ maintenance', 'Dramatic PFS benefit in BRCA+', 'Expanding to HRD+ populations'],
    weaknesses: ['MDS/AML risk (1-2%)', 'Hematologic toxicity', 'Label restricted after PARP safety review'],
    source: 'FDA label; SOLO-1/PAOLA-1 trials; AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zejula',
    generic_name: 'niraparib',
    company: 'GSK',
    indication: 'Ovarian Cancer',
    indication_specifics: '1L maintenance advanced ovarian post-platinum response; 2L+ maintenance',
    mechanism: 'PARP inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'PARP1/2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'PRIMA: 1L maintenance PFS 13.8 vs 8.2 mo all-comers (HR 0.62); HRD+ PFS 21.9 vs 10.4 mo',
    line_of_therapy: 'maintenance',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Biomarker-agnostic initial label', 'Once-daily oral dosing', 'Companion diagnostic with HRD test'],
    weaknesses: ['Label narrowed to HRD+ after FDA safety review', 'Thrombocytopenia management', 'Losing market share to Lynparza'],
    source: 'FDA label; PRIMA trial; GSK 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Avastin',
    generic_name: 'bevacizumab',
    company: 'Roche/Genentech',
    indication: 'Ovarian Cancer',
    indication_specifics: '1L + chemo and maintenance in Stage III/IV ovarian cancer; platinum-sensitive recurrence',
    mechanism: 'Anti-VEGF monoclonal antibody',
    mechanism_category: 'anti_vegf',
    molecular_target: 'VEGF-A',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'GOG-0218: PFS 14.1 vs 10.3 mo with bev maintenance (HR 0.72); PAOLA-1: bev+olaparib PFS 22.1 mo in HRD+',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Established anti-VEGF in ovarian', 'Combination partner with PARPi', 'Broad label coverage'],
    weaknesses: ['GI perforation risk', 'Hypertension', 'Biosimilar competition', 'No OS benefit as monotherapy add-on'],
    source: 'FDA label; GOG-0218/PAOLA-1 trials; Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Mirvetuximab Soravtansine',
    generic_name: 'mirvetuximab soravtansine',
    company: 'ImmunoGen (AbbVie)',
    indication: 'Ovarian Cancer',
    indication_specifics: 'FRa-high platinum-resistant ovarian cancer',
    mechanism: 'ADC (Folate Receptor alpha)',
    mechanism_category: 'adc',
    molecular_target: 'Folate Receptor alpha',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'SORAYA: ORR 32.4% in FRa-high platinum-resistant; MIRASOL: OS 16.5 vs 12.7 mo vs chemo (HR 0.67)',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First FRa-targeted therapy', 'OS benefit in platinum-resistant', 'Novel ADC in ovarian'],
    weaknesses: ['FRa testing infrastructure needed', 'Ocular toxicity (blurred vision)', 'Limited to FRa-high (~35-40%)'],
    source: 'FDA label; SORAYA/MIRASOL trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // COLORECTAL CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Avastin',
    generic_name: 'bevacizumab',
    company: 'Roche/Genentech',
    indication: 'Colorectal Cancer',
    indication_specifics: '1L/2L metastatic CRC + chemotherapy backbone (FOLFOX/FOLFIRI)',
    mechanism: 'Anti-VEGF monoclonal antibody',
    mechanism_category: 'anti_vegf',
    molecular_target: 'VEGF-A',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'AVF2107g: mOS 20.3 vs 15.6 mo with bev+IFL vs IFL (HR 0.66) in 1L mCRC',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Backbone of 1L mCRC for 20 years', 'Broadly combined with chemo regimens', 'Biosimilar availability lowers cost'],
    weaknesses: ['GI perforation risk', 'No biomarker for selection', 'Biosimilar erosion of branded revenue'],
    source: 'FDA label; AVF2107g trial; Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Erbitux',
    generic_name: 'cetuximab',
    company: 'Eli Lilly',
    indication: 'Colorectal Cancer',
    indication_specifics: '1L RAS wild-type mCRC (left-sided) + FOLFIRI/FOLFOX',
    mechanism: 'Anti-EGFR monoclonal antibody',
    mechanism_category: 'anti_egfr',
    molecular_target: 'EGFR',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CRYSTAL: PFS 9.9 vs 8.4 mo with FOLFIRI+cetuximab vs FOLFIRI (HR 0.68 in KRAS WT)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Standard in left-sided RAS WT CRC', 'Deep responses enabling resection', 'Long clinical track record'],
    weaknesses: ['Right-sided tumors have poor response', 'Infusion reactions', 'Skin toxicity management'],
    source: 'FDA label; CRYSTAL/FIRE-3 trials; Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Opdivo + Yervoy',
    generic_name: 'nivolumab + ipilimumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Colorectal Cancer',
    indication_specifics: '1L MSI-H/dMMR metastatic CRC',
    mechanism: 'PD-1 + CTLA-4 dual checkpoint inhibitor',
    mechanism_category: 'checkpoint_inhibitor_combo',
    molecular_target: 'PD-1/CTLA-4',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'CheckMate-8HW: 1L MSI-H mCRC PFS NR vs 5.9 mo chemo (HR 0.21); ORR 69%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Chemo-free option in MSI-H', 'Dramatic PFS benefit', 'Durable complete responses'],
    weaknesses: ['MSI-H only ~15% of mCRC', 'High immune-related toxicity', 'Cost of dual checkpoint'],
    source: 'FDA label; CheckMate-8HW trial; BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Colorectal Cancer',
    indication_specifics: '1L MSI-H/dMMR unresectable or metastatic CRC',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'KEYNOTE-177: 1L MSI-H mCRC PFS 16.5 vs 8.2 mo vs chemo (HR 0.60)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First 1L IO monotherapy in MSI-H CRC', 'Pembro franchise familiarity', 'Strong PFS benefit'],
    weaknesses: ['MSI-H only ~15% of mCRC', 'No OS benefit reached (crossover)', 'Nivo+ipi may be preferred'],
    source: 'FDA label; KEYNOTE-177 trial; Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Stivarga',
    generic_name: 'regorafenib',
    company: 'Bayer',
    indication: 'Colorectal Cancer',
    indication_specifics: '3L+ mCRC after fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF, anti-EGFR (if RAS WT)',
    mechanism: 'Multi-kinase inhibitor (VEGFR, TIE2, RAF, PDGFR, FGFR, KIT)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'VEGFR/TIE2/RAF',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CORRECT: mOS 6.4 vs 5.0 mo vs placebo (HR 0.77) in refractory mCRC',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Established late-line option', 'Oral dosing', 'Active across biomarker subgroups'],
    weaknesses: ['Modest OS benefit (~1.4 months)', 'Hand-foot syndrome', 'Fatigue and hepatotoxicity', 'Limited use in practice'],
    source: 'FDA label; CORRECT trial; Bayer 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // PARKINSON'S DISEASE (additional entries)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Sinemet',
    generic_name: 'carbidopa/levodopa',
    company: 'Generic (Merck originator)',
    indication: "Parkinson's Disease",
    indication_specifics: 'Motor symptoms of PD (gold standard symptomatic therapy)',
    mechanism: 'Dopamine precursor + DOPA decarboxylase inhibitor',
    mechanism_category: 'dopamine_replacement',
    molecular_target: 'Dopamine pathway',
    phase: 'Approved',
    primary_endpoint: 'UPDRS Part III',
    key_data: 'Gold standard for >50 years; most effective motor symptom control; all PD patients eventually require L-dopa',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Most effective motor symptom treatment', 'Decades of experience', 'Generic availability', 'Multiple formulations (IR, CR, ER)'],
    weaknesses: ['Motor fluctuations with chronic use', 'Dyskinesia development', 'Wearing-off phenomenon', 'Does not modify disease'],
    source: 'FDA label; AAN Practice Guidelines',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ongentys',
    generic_name: 'opicapone',
    company: 'Neurocrine Biosciences/BIAL',
    indication: "Parkinson's Disease",
    indication_specifics: 'Adjunct to levodopa/carbidopa in PD patients experiencing OFF episodes',
    mechanism: 'COMT inhibitor (3rd-generation)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'COMT',
    phase: 'Approved',
    primary_endpoint: 'OFF time reduction',
    key_data: 'BIPARK-1/2: OFF time reduction -60 min vs placebo; no hepatotoxicity signal unlike tolcapone',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Once-daily dosing', 'No hepatotoxicity monitoring needed', 'Effective OFF time reduction'],
    weaknesses: ['Modest effect size', 'Dyskinesia worsening', 'Competitive with entacapone/safinamide'],
    source: 'FDA label; BIPARK trials; Neurocrine 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nuplazid',
    generic_name: 'pimavanserin',
    company: 'Acadia Pharmaceuticals',
    indication: "Parkinson's Disease",
    indication_specifics: 'Hallucinations and delusions associated with PD psychosis',
    mechanism: 'Selective 5-HT2A inverse agonist',
    mechanism_category: 'serotonin_modulator',
    molecular_target: '5-HT2A',
    phase: 'Approved',
    primary_endpoint: 'SAPS-PD',
    key_data: 'Study 020: SAPS-PD -5.79 vs -2.73 placebo (p=0.001); no motor worsening',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Only FDA-approved therapy for PD psychosis', 'No motor worsening', 'Selective mechanism avoids dopamine blockade'],
    weaknesses: ['QTc prolongation warning', 'Boxed warning for elderly dementia mortality', 'Modest effect size'],
    source: 'FDA label; Study 020; Acadia 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Produodopa',
    generic_name: 'foslevodopa/foscarbidopa',
    company: 'AbbVie',
    indication: "Parkinson's Disease",
    indication_specifics: 'Advanced PD with motor fluctuations; 24-hour SC infusion',
    mechanism: 'Subcutaneous levodopa/carbidopa continuous infusion (prodrug)',
    mechanism_category: 'dopamine_replacement',
    molecular_target: 'Dopamine pathway',
    phase: 'Approved',
    primary_endpoint: 'ON time without troublesome dyskinesia',
    key_data: 'Phase 3: +1.75 hr ON time vs +0.45 hr oral LD/CD (p<0.001); significant OFF time reduction',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Continuous drug delivery reduces fluctuations', 'Subcutaneous (no intestinal tube like Duodopa)', '24-hour pump option'],
    weaknesses: ['Infusion site reactions (90%+)', 'Device burden', 'High cost vs oral levodopa'],
    source: 'FDA label; Phase 3 trial; AbbVie 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // MULTIPLE SCLEROSIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Ocrevus',
    generic_name: 'ocrelizumab',
    company: 'Roche/Genentech',
    indication: 'Multiple Sclerosis',
    indication_specifics: 'Relapsing MS and primary progressive MS (PPMS)',
    mechanism: 'Anti-CD20 monoclonal antibody',
    mechanism_category: 'anti_cd20',
    molecular_target: 'CD20',
    phase: 'Approved',
    primary_endpoint: 'ARR',
    key_data: 'OPERA I/II: ARR 0.16 vs 0.29 IFN-b1a (46% reduction); ORATORIO: PPMS disability progression HR 0.76',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Only approved therapy for PPMS', 'High efficacy in RMS', '$6B+ blockbuster', 'Every 6 month dosing'],
    weaknesses: ['Infusion reactions', 'Infection risk (hypogammaglobulinemia)', 'No oral formulation'],
    source: 'FDA label; OPERA/ORATORIO trials; Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Kesimpta',
    generic_name: 'ofatumumab',
    company: 'Novartis',
    indication: 'Multiple Sclerosis',
    indication_specifics: 'Relapsing MS in adults',
    mechanism: 'Anti-CD20 monoclonal antibody (subcutaneous)',
    mechanism_category: 'anti_cd20',
    molecular_target: 'CD20',
    phase: 'Approved',
    primary_endpoint: 'ARR',
    key_data: 'ASCLEPIOS I/II: ARR 0.11 vs 0.22 teriflunomide (50.5% reduction); Gd+ lesions 97.5% reduction',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Self-administered SC injection at home', 'Rapid B-cell depletion', 'Superior to teriflunomide'],
    weaknesses: ['Monthly injections', 'Infection risk with B-cell depletion', 'No PPMS indication'],
    source: 'FDA label; ASCLEPIOS trials; Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tysabri',
    generic_name: 'natalizumab',
    company: 'Biogen',
    indication: 'Multiple Sclerosis',
    indication_specifics: 'Relapsing MS, typically as monotherapy for highly active disease',
    mechanism: 'Anti-alpha4 integrin monoclonal antibody',
    mechanism_category: 'anti_integrin',
    molecular_target: 'Alpha4 integrin',
    phase: 'Approved',
    primary_endpoint: 'ARR',
    key_data: 'AFFIRM: ARR 68% reduction vs placebo; 42% reduction in disability progression',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Highly effective in active RRMS', 'Rapid onset of action', 'Long clinical track record'],
    weaknesses: ['PML risk (JCV antibody monitoring required)', 'REMS program', 'Revenue declining with anti-CD20 competition'],
    source: 'FDA label; AFFIRM trial; Biogen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Mavenclad',
    generic_name: 'cladribine',
    company: 'Merck KGaA',
    indication: 'Multiple Sclerosis',
    indication_specifics: 'Highly active relapsing MS',
    mechanism: 'Purine nucleoside analog (selective lymphocyte depletion)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'Lymphocyte DNA',
    phase: 'Approved',
    primary_endpoint: 'ARR',
    key_data: 'CLARITY: ARR 0.14 vs 0.33 placebo (57.6% reduction); disability progression HR 0.67',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Oral short-course dosing (10 days/year for 2 years)', 'No continuous therapy needed', 'Durable effect after completion'],
    weaknesses: ['Lymphopenia management', 'Herpes zoster risk', 'Cancer risk theoretical concern', 'Restricted to highly active MS'],
    source: 'FDA label; CLARITY trial; Merck KGaA 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Briumvi',
    generic_name: 'ublituximab',
    company: 'TG Therapeutics',
    indication: 'Multiple Sclerosis',
    indication_specifics: 'Relapsing MS in adults',
    mechanism: 'Anti-CD20 monoclonal antibody (glycoengineered)',
    mechanism_category: 'anti_cd20',
    molecular_target: 'CD20',
    phase: 'Approved',
    primary_endpoint: 'ARR',
    key_data: 'ULTIMATE I/II: ARR 0.076 vs 0.188 teriflunomide (59% reduction); 1-hour infusion',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['1-hour infusion (shorter than Ocrevus)', 'Strong efficacy vs teriflunomide', 'Cost-competitive positioning'],
    weaknesses: ['Late entrant in anti-CD20 class', 'Limited differentiation from Ocrevus/Kesimpta', 'Infusion site needed'],
    source: 'FDA label; ULTIMATE trials; TG Therapeutics 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // EPILEPSY
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Epidiolex',
    generic_name: 'cannabidiol',
    company: 'Jazz Pharmaceuticals (GW Pharma)',
    indication: 'Epilepsy',
    indication_specifics: 'Seizures associated with Lennox-Gastaut, Dravet syndrome, or tuberous sclerosis complex (age >= 1 yr)',
    mechanism: 'Cannabinoid (exact mechanism in epilepsy unclear; modulates GPR55, TRPV1, adenosine)',
    mechanism_category: 'cannabinoid',
    molecular_target: 'GPR55/TRPV1',
    phase: 'Approved',
    primary_endpoint: 'Seizure frequency reduction',
    key_data: 'GWPCARE1 (Dravet): 39% median seizure reduction vs 13% placebo; GWPCARE3 (LGS): 44% drop seizure reduction',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First FDA-approved cannabinoid', 'Active in treatment-resistant epilepsy syndromes', 'Favorable safety vs clobazam'],
    weaknesses: ['Drug-drug interactions (clobazam levels)', 'Hepatotoxicity with valproate', 'Somnolence', 'Schedule V controlled'],
    source: 'FDA label; GWPCARE trials; Jazz Pharma 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Fycompa',
    generic_name: 'perampanel',
    company: 'Eisai',
    indication: 'Epilepsy',
    indication_specifics: 'Adjunctive therapy for partial-onset and primary generalized tonic-clonic seizures (age >= 4)',
    mechanism: 'Non-competitive AMPA glutamate receptor antagonist',
    mechanism_category: 'glutamate_modulator',
    molecular_target: 'AMPA receptor',
    phase: 'Approved',
    primary_endpoint: 'Seizure frequency reduction',
    key_data: 'Phase 3 (304/305/306): median seizure reduction 23-28% vs placebo at 8mg; 50% responder rate 33-38%',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First-in-class AMPA antagonist', 'Once-daily dosing', 'Effective in focal and generalized epilepsy'],
    weaknesses: ['Behavioral/psychiatric adverse events (aggression, hostility)', 'Dizziness', 'Boxed warning for serious psychiatric events'],
    source: 'FDA label; Phase 3 trials 304/305/306; Eisai 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Briviact',
    generic_name: 'brivaracetam',
    company: 'UCB',
    indication: 'Epilepsy',
    indication_specifics: 'Adjunctive therapy for partial-onset seizures in patients >= 1 month',
    mechanism: 'Synaptic vesicle protein 2A (SV2A) ligand',
    mechanism_category: 'sv2a_ligand',
    molecular_target: 'SV2A',
    phase: 'Approved',
    primary_endpoint: 'Seizure frequency reduction',
    key_data: 'Phase 3 (N01252/N01253): 50% responder rate 32.7-38.9% at 100-200mg vs 20.3-21.6% placebo',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Higher affinity for SV2A than levetiracetam', 'Fewer behavioral side effects than levetiracetam', 'Rapid onset'],
    weaknesses: ['Modest differentiation from generic levetiracetam', 'Somnolence/fatigue', 'Premium pricing vs generic LEV'],
    source: 'FDA label; Phase 3 trials; UCB 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Xcopri',
    generic_name: 'cenobamate',
    company: 'SK Life Science',
    indication: 'Epilepsy',
    indication_specifics: 'Partial-onset seizures in adults',
    mechanism: 'Dual mechanism: sodium channel modulation + positive allosteric modulation of GABA-A receptors',
    mechanism_category: 'sodium_channel_modulator',
    molecular_target: 'Nav channels/GABA-A',
    phase: 'Approved',
    primary_endpoint: 'Seizure frequency reduction',
    key_data: 'C017: seizure-free rate 21.1% at 400mg vs 1.0% placebo; 50% responder rate 64%',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Highest seizure-free rates of any adjunctive ASM', 'Dual mechanism of action', 'Strong efficacy signal'],
    weaknesses: ['DRESS syndrome risk (slow titration required)', 'Somnolence/dizziness', 'REMS program for titration'],
    source: 'FDA label; C017 trial; SK Life Science 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // MIGRAINE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Aimovig',
    generic_name: 'erenumab',
    company: 'Amgen/Novartis',
    indication: 'Migraine',
    indication_specifics: 'Preventive treatment of migraine in adults (episodic and chronic)',
    mechanism: 'Anti-CGRP receptor monoclonal antibody',
    mechanism_category: 'anti_cgrp',
    molecular_target: 'CGRP receptor',
    phase: 'Approved',
    primary_endpoint: 'Monthly migraine days reduction',
    key_data: 'STRIVE: -3.2 vs -1.8 MMD reduction (140mg); LIBERTY: 30.3% vs 14.0% 50% responder rate in treatment-resistant',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First-in-class anti-CGRP', 'Monthly SC self-injection', 'Favorable tolerability vs oral preventives'],
    weaknesses: ['Constipation (unique to receptor-targeted approach)', 'High cost vs generic oral preventives', 'Payer prior auth requirements'],
    source: 'FDA label; STRIVE trial; Amgen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ajovy',
    generic_name: 'fremanezumab',
    company: 'Teva',
    indication: 'Migraine',
    indication_specifics: 'Preventive treatment of migraine in adults',
    mechanism: 'Anti-CGRP ligand monoclonal antibody',
    mechanism_category: 'anti_cgrp',
    molecular_target: 'CGRP ligand',
    phase: 'Approved',
    primary_endpoint: 'Monthly migraine days reduction',
    key_data: 'HALO-EM: -3.7 vs -2.2 MMD reduction (monthly); HALO-CM: -4.6 vs -2.5 MMD (monthly dosing)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Monthly or quarterly dosing flexibility', 'No constipation signal', 'Effective in chronic migraine'],
    weaknesses: ['Injection site reactions', 'Crowded anti-CGRP class', 'Modest differentiation from peers'],
    source: 'FDA label; HALO trials; Teva 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Emgality',
    generic_name: 'galcanezumab',
    company: 'Eli Lilly',
    indication: 'Migraine',
    indication_specifics: 'Preventive treatment of migraine; episodic cluster headache',
    mechanism: 'Anti-CGRP ligand monoclonal antibody',
    mechanism_category: 'anti_cgrp',
    molecular_target: 'CGRP ligand',
    phase: 'Approved',
    primary_endpoint: 'Monthly migraine days reduction',
    key_data: 'EVOLVE-1/2: -4.7 vs -2.8 MMD reduction (EM); REGAIN: -4.6 vs -2.7 MMD (CM); cluster headache reduction',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Only anti-CGRP approved for cluster headache', 'Loading dose for rapid onset', 'Strong efficacy across EM and CM'],
    weaknesses: ['Monthly injection required', 'Injection site reactions', 'Premium pricing'],
    source: 'FDA label; EVOLVE/REGAIN trials; Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nurtec ODT',
    generic_name: 'rimegepant',
    company: 'Pfizer (Biohaven)',
    indication: 'Migraine',
    indication_specifics: 'Acute treatment and preventive treatment of episodic migraine',
    mechanism: 'CGRP receptor antagonist (oral small molecule, gepant)',
    mechanism_category: 'gepant',
    molecular_target: 'CGRP receptor',
    phase: 'Approved',
    primary_endpoint: 'Pain freedom at 2 hours',
    key_data: 'Acute: 21% pain-free at 2h vs 11% placebo; Prevention: -4.3 vs -3.5 MMD reduction (every other day dosing)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Dual acute+preventive indication', 'Oral dissolving tablet convenience', 'No medication overuse headache risk'],
    weaknesses: ['Every-other-day preventive dosing compliance', 'Nausea', 'Premium pricing vs generic triptans for acute'],
    source: 'FDA label; Biohaven trials; Pfizer 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // PLAQUE PSORIASIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Skyrizi',
    generic_name: 'risankizumab',
    company: 'AbbVie',
    indication: 'Plaque Psoriasis',
    indication_specifics: 'Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy',
    mechanism: 'Anti-IL-23 (p19) monoclonal antibody',
    mechanism_category: 'anti_il23',
    molecular_target: 'IL-23 (p19)',
    phase: 'Approved',
    primary_endpoint: 'PASI 90',
    key_data: 'UltIMMa-1/2: PASI 90 75% vs 5% placebo at 16 wk; IMMvent: superior to adalimumab (PASI 90 72% vs 47%)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Best-in-class PASI 90 rates', 'Every 12-week maintenance dosing', 'Clean safety profile'],
    weaknesses: ['Late entrant vs Stelara/Cosentyx', 'SC administration', 'Premium pricing in crowded market'],
    source: 'FDA label; UltIMMa trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tremfya',
    generic_name: 'guselkumab',
    company: 'Johnson & Johnson',
    indication: 'Plaque Psoriasis',
    indication_specifics: 'Moderate-to-severe plaque psoriasis in adults',
    mechanism: 'Anti-IL-23 (p19) monoclonal antibody',
    mechanism_category: 'anti_il23',
    molecular_target: 'IL-23 (p19)',
    phase: 'Approved',
    primary_endpoint: 'IGA 0/1',
    key_data: 'VOYAGE 1/2: IGA 0/1 85.1% vs 6.9% placebo at 16 wk; superior to Humira',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First anti-IL-23 in psoriasis', 'Every 8-week dosing', 'Expanding to IBD'],
    weaknesses: ['Slightly lower PASI 90 vs Skyrizi', 'SC administration', 'Competitive with Skyrizi for share'],
    source: 'FDA label; VOYAGE trials; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cosentyx',
    generic_name: 'secukinumab',
    company: 'Novartis',
    indication: 'Plaque Psoriasis',
    indication_specifics: 'Moderate-to-severe plaque psoriasis in adults',
    mechanism: 'Anti-IL-17A monoclonal antibody',
    mechanism_category: 'anti_il17',
    molecular_target: 'IL-17A',
    phase: 'Approved',
    primary_endpoint: 'PASI 75',
    key_data: 'ERASURE/FIXTURE: PASI 75 81.6% vs 4.5% placebo at 12 wk; superior to etanercept',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First anti-IL-17 approved', 'Rapid onset of action', 'Multiple autoimmune indications (PsA, AS, nr-axSpA)'],
    weaknesses: ['Candida infection risk', 'IBD contraindication', 'Losing share to IL-23 class'],
    source: 'FDA label; ERASURE/FIXTURE trials; Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Taltz',
    generic_name: 'ixekizumab',
    company: 'Eli Lilly',
    indication: 'Plaque Psoriasis',
    indication_specifics: 'Moderate-to-severe plaque psoriasis in adults',
    mechanism: 'Anti-IL-17A monoclonal antibody',
    mechanism_category: 'anti_il17',
    molecular_target: 'IL-17A',
    phase: 'Approved',
    primary_endpoint: 'PASI 75',
    key_data: 'UNCOVER-2/3: PASI 90 71% vs 1% placebo at 12 wk; IXORA-S: superior to Stelara at week 24',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['High PASI 100 (complete clearance) rates', 'Rapid response (Week 1-4)', 'Head-to-head superiority vs ustekinumab'],
    weaknesses: ['Injection frequency (loading phase)', 'Candida risk', 'IBD concern with IL-17 class'],
    source: 'FDA label; UNCOVER trials; Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Bimzelx',
    generic_name: 'bimekizumab',
    company: 'UCB',
    indication: 'Plaque Psoriasis',
    indication_specifics: 'Moderate-to-severe plaque psoriasis in adults',
    mechanism: 'Dual IL-17A and IL-17F inhibitor',
    mechanism_category: 'anti_il17',
    molecular_target: 'IL-17A/IL-17F',
    phase: 'Approved',
    primary_endpoint: 'PASI 90',
    key_data: 'BE VIVID: PASI 90 85% vs 50% ustekinumab at 16 wk; BE SURE: PASI 100 60% at 16 wk',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Highest skin clearance rates (PASI 100)', 'Dual IL-17A+F inhibition', 'Every 8-week maintenance after loading'],
    weaknesses: ['Oral candidiasis rate (~15%)', 'IBD class concern', 'Late entrant in crowded biologics market'],
    source: 'FDA label; BE VIVID/BE SURE trials; UCB 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // CROHN'S DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Stelara',
    generic_name: 'ustekinumab',
    company: 'Johnson & Johnson',
    indication: "Crohn's Disease",
    indication_specifics: 'Moderately to severely active CD in adults who failed or were intolerant to TNFi or corticosteroids',
    mechanism: 'Anti-IL-12/23 (p40) monoclonal antibody',
    mechanism_category: 'anti_il12_23',
    molecular_target: 'IL-12/IL-23 (p40)',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission (CDAI < 150)',
    key_data: 'UNITI-1/2: clinical remission 34.3% vs 21.5% placebo at 8 wk; IM-UNITI: 53.1% remission at 44 wk maintenance',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Established efficacy in anti-TNF failures', 'Clean safety profile', 'Every 8-week SC maintenance'],
    weaknesses: ['Biosimilar competition emerging 2025', 'Lower efficacy vs newer agents in head-to-head', 'Revenue declining'],
    source: 'FDA label; UNITI/IM-UNITI trials; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Skyrizi',
    generic_name: 'risankizumab',
    company: 'AbbVie',
    indication: "Crohn's Disease",
    indication_specifics: 'Moderately to severely active CD in adults',
    mechanism: 'Anti-IL-23 (p19) monoclonal antibody',
    mechanism_category: 'anti_il23',
    molecular_target: 'IL-23 (p19)',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission (CDAI < 150)',
    key_data: 'ADVANCE/MOTIVATE: clinical remission 43-45% vs 20-25% placebo at 12 wk; FORTIFY: 52% endoscopic remission at 52 wk',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong endoscopic remission rates', 'Clean safety profile', 'Rapid market share gain in CD'],
    weaknesses: ['IV induction required', 'Premium pricing', 'Competition with other IL-23 agents'],
    source: 'FDA label; ADVANCE/MOTIVATE/FORTIFY trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Entyvio',
    generic_name: 'vedolizumab',
    company: 'Takeda',
    indication: "Crohn's Disease",
    indication_specifics: 'Moderately to severely active CD in adults after conventional therapy failure',
    mechanism: 'Anti-alpha4beta7 integrin monoclonal antibody',
    mechanism_category: 'anti_integrin',
    molecular_target: 'Alpha4beta7',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission',
    key_data: 'GEMINI 2: clinical remission 39.0% vs 21.6% placebo at 52 wk; gut-selective safety advantage',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Gut-selective mechanism (systemic safety advantage)', 'SC formulation available', 'Strong evidence in maintenance'],
    weaknesses: ['Slower onset than anti-TNF', 'Less effective in fistulizing CD', 'Biosimilar risk approaching'],
    source: 'FDA label; GEMINI 2 trial; Takeda 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Humira',
    generic_name: 'adalimumab',
    company: 'AbbVie',
    indication: "Crohn's Disease",
    indication_specifics: 'Moderately to severely active CD in adults; fistulizing CD; pediatric CD',
    mechanism: 'Anti-TNF monoclonal antibody',
    mechanism_category: 'anti_tnf',
    molecular_target: 'TNF-alpha',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission',
    key_data: 'CLASSIC I: 36% remission vs 12% placebo at 4 wk; CHARM: 40% remission at 56 wk',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Decades of clinical experience', 'Pediatric and fistulizing indications', 'Biosimilar cost reduction'],
    weaknesses: ['10+ biosimilars eroding revenue', 'Secondary loss of response common', 'Immunogenicity with anti-drug antibodies'],
    source: 'FDA label; CLASSIC/CHARM trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rinvoq',
    generic_name: 'upadacitinib',
    company: 'AbbVie',
    indication: "Crohn's Disease",
    indication_specifics: 'Moderately to severely active CD in adults after TNFi inadequate response/intolerance',
    mechanism: 'JAK1 inhibitor (selective)',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission',
    key_data: 'U-EXCEL/U-EXCEED: clinical remission 49-50% vs 29-34% placebo at 12 wk; U-ENDURE: 52% endoscopic response at 52 wk',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Oral administration (no injection/infusion)', 'Rapid onset of action', 'Strong endoscopic outcomes'],
    weaknesses: ['JAK class boxed warning', 'Herpes zoster risk', 'Restricted to post-TNFi population in CD label'],
    source: 'FDA label; U-EXCEL/U-EXCEED/U-ENDURE trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // CYSTIC FIBROSIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Trikafta',
    generic_name: 'elexacaftor/tezacaftor/ivacaftor',
    company: 'Vertex Pharmaceuticals',
    indication: 'Cystic Fibrosis',
    indication_specifics: 'CF patients age >= 2 with at least one F508del CFTR mutation (~90% of CF patients)',
    mechanism: 'Triple CFTR modulator (corrector/corrector/potentiator)',
    mechanism_category: 'cftr_modulator',
    molecular_target: 'CFTR',
    phase: 'Approved',
    primary_endpoint: 'ppFEV1 improvement',
    key_data: 'VX-445-102: ppFEV1 +14.3% vs placebo in F508del/minimal function; sweat chloride -41.8 mmol/L',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Transformative efficacy', 'Addresses ~90% of CF patients', '$9B+ blockbuster', 'Dramatic improvement in lung function and quality of life'],
    weaknesses: ['~10% of CF patients with non-responsive mutations', 'Hepatotoxicity monitoring', 'Very high annual cost ($300K+)', 'Vertex monopoly concerns'],
    source: 'FDA label; VX-445 trials; Vertex 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vanzacaftor/Tezacaftor/Deutivacaftor',
    generic_name: 'vanzacaftor/tezacaftor/deutivacaftor',
    company: 'Vertex Pharmaceuticals',
    indication: 'Cystic Fibrosis',
    indication_specifics: 'CF patients age >= 6 with at least one F508del CFTR mutation',
    mechanism: 'Next-gen triple CFTR modulator (once-daily)',
    mechanism_category: 'cftr_modulator',
    molecular_target: 'CFTR',
    phase: 'Approved',
    primary_endpoint: 'ppFEV1 improvement',
    key_data: 'SKYLINE: non-inferior to Trikafta with once-daily dosing; ppFEV1 maintained',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Once-daily dosing (vs twice-daily Trikafta)', 'Improved compliance potential', 'Patent life extension for Vertex'],
    weaknesses: ['No superiority over Trikafta', 'Vertex self-competition', 'Same mutation coverage limitations'],
    source: 'FDA label; SKYLINE trial; Vertex 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'ABBV-119 (CFTR mRNA)',
    company: 'AbbVie',
    indication: 'Cystic Fibrosis',
    indication_specifics: 'CF patients with nonsense/splice mutations not responsive to CFTR modulators',
    mechanism: 'mRNA therapy delivering functional CFTR protein',
    mechanism_category: 'mrna_therapy',
    molecular_target: 'CFTR (mRNA replacement)',
    phase: 'Phase 1/2',
    primary_endpoint: 'CFTR function (sweat chloride, nasal potential difference)',
    key_data: 'Preclinical: restored CFTR function in human bronchial epithelial cells; Phase 1 inhaled delivery',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Mutation-agnostic approach', 'Could address all CF patients including non-F508del', 'Novel modality'],
    weaknesses: ['Very early stage', 'Inhaled mRNA delivery challenges', 'Repeat dosing likely needed', 'Lung targeting efficiency unknown'],
    source: 'AbbVie pipeline; preclinical/Phase 1 data 2024',
    last_updated: '2024-10-01',
  },
  {
    asset_name: 'Pulmozyme',
    generic_name: 'dornase alfa',
    company: 'Roche/Genentech',
    indication: 'Cystic Fibrosis',
    indication_specifics: 'Adjunctive therapy to improve pulmonary function in CF patients',
    mechanism: 'Recombinant human DNase I (mucolytic)',
    mechanism_category: 'mucolytic',
    molecular_target: 'Extracellular DNA',
    phase: 'Approved',
    primary_endpoint: 'FEV1 improvement',
    key_data: 'Pivotal trial: 5.8% improvement in FEV1 at 6 mo; reduced exacerbation frequency by 28%',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Established standard adjunctive therapy', 'Well-tolerated', 'Complementary to CFTR modulators'],
    weaknesses: ['Nebulizer administration burden', 'Modest lung function improvement', 'Symptomatic not disease-modifying'],
    source: 'FDA label; Roche 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // HEMOPHILIA A
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Hemlibra',
    generic_name: 'emicizumab',
    company: 'Roche/Genentech',
    indication: 'Hemophilia A',
    indication_specifics: 'Routine prophylaxis in hemophilia A with and without factor VIII inhibitors',
    mechanism: 'Bispecific antibody mimicking factor VIIIa (bridges FIXa and FX)',
    mechanism_category: 'bispecific',
    molecular_target: 'FIXa/FX',
    phase: 'Approved',
    primary_endpoint: 'Annualized bleeding rate (ABR)',
    key_data: 'HAVEN 1: ABR 2.9 with emicizumab vs 23.3 with no prophylaxis (87% reduction) in inhibitor patients; HAVEN 3: 68% reduction vs FVIII prophylaxis',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['SC administration weekly/biweekly/monthly', 'Active in inhibitor patients', '$4B+ blockbuster', 'Transformed hemophilia prophylaxis'],
    weaknesses: ['Thrombotic microangiopathy risk with aPCC', 'Does not replace factor for surgery/acute bleeds', 'Very high cost'],
    source: 'FDA label; HAVEN trials; Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Fitusiran',
    generic_name: 'fitusiran',
    company: 'Sanofi',
    indication: 'Hemophilia A',
    indication_specifics: 'Routine prophylaxis in hemophilia A or B with and without inhibitors',
    mechanism: 'Anti-antithrombin siRNA (rebalances hemostasis)',
    mechanism_category: 'sirna',
    molecular_target: 'Antithrombin (SERPINC1)',
    phase: 'Approved',
    primary_endpoint: 'ABR',
    key_data: 'ATLAS-A/B: ABR 1.7 (Hem A w/ inhibitors) and 1.4 (Hem A w/o inhibitors); once-monthly SC dosing',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Novel mechanism (rebalancing)', 'Cross-hemophilia (A and B)', 'Once-monthly SC injection'],
    weaknesses: ['Thrombotic events (fatal sinus thrombosis in trial)', 'Boxed warning for thrombosis', 'AT monitoring required'],
    source: 'FDA label; ATLAS trials; Sanofi 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Roctavian',
    generic_name: 'valoctocogene roxaparvovec',
    company: 'BioMarin',
    indication: 'Hemophilia A',
    indication_specifics: 'Severe hemophilia A (FVIII < 1 IU/dL) in adults without FVIII inhibitors and AAV5 antibody negative',
    mechanism: 'AAV5 gene therapy (FVIII gene delivery)',
    mechanism_category: 'gene_therapy',
    molecular_target: 'FVIII (F8 gene)',
    phase: 'Approved',
    primary_endpoint: 'Factor VIII activity level',
    key_data: 'GENEr8-1: median FVIII 41.9 IU/dL at Year 2; ABR 0.8; 96% of patients discontinued FVIII prophylaxis',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['One-time curative potential', 'Dramatic bleed reduction', 'Freedom from prophylaxis'],
    weaknesses: ['FVIII levels decline over time', 'Hepatotoxicity (ALT elevations)', '$2.9M price', 'AAV5 seropositive patients excluded', 'Long-term durability uncertain'],
    source: 'FDA label; GENEr8-1 trial; BioMarin 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Esperoct',
    generic_name: 'turoctocog alfa pegol',
    company: 'Novo Nordisk',
    indication: 'Hemophilia A',
    indication_specifics: 'Routine prophylaxis and on-demand treatment in hemophilia A (PEGylated FVIII)',
    mechanism: 'PEGylated recombinant factor VIII',
    mechanism_category: 'clotting_factor',
    molecular_target: 'Factor VIII (replacement)',
    phase: 'Approved',
    primary_endpoint: 'ABR',
    key_data: 'pathfinder 2: ABR 1.18 with every-4-day prophylaxis; 40-hour half-life (extended vs standard FVIII)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Extended half-life reduces injection frequency', 'Established FVIII replacement approach', 'Effective for bleeds and surgery'],
    weaknesses: ['Still requires IV injection', 'Inhibitor development risk', 'Losing share to non-factor therapies (Hemlibra)'],
    source: 'FDA label; pathfinder trials; Novo Nordisk 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // DUCHENNE MUSCULAR DYSTROPHY
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Elevidys',
    generic_name: 'delandistrogene moxeparvovec',
    company: 'Sarepta Therapeutics',
    indication: 'Duchenne Muscular Dystrophy',
    indication_specifics: 'DMD in ambulatory patients aged 4-5 years (confirmed FDA approval 2024)',
    mechanism: 'AAV-based gene therapy (micro-dystrophin gene delivery)',
    mechanism_category: 'gene_therapy',
    molecular_target: 'Dystrophin (micro-dystrophin)',
    phase: 'Approved',
    primary_endpoint: 'Micro-dystrophin expression / NSAA',
    key_data: 'EMBARK: micro-dystrophin expression in 96% of patients; NSAA change +1.7 vs -0.5 placebo (ages 4-5)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First gene therapy for DMD', 'One-time administration', 'Meaningful micro-dystrophin expression'],
    weaknesses: ['$3.2M price', 'Narrow approved age range', 'Durability of expression unknown long-term', 'Immune response to AAV'],
    source: 'FDA label; EMBARK trial; Sarepta 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Exondys 51',
    generic_name: 'eteplirsen',
    company: 'Sarepta Therapeutics',
    indication: 'Duchenne Muscular Dystrophy',
    indication_specifics: 'DMD patients with confirmed exon 51 skipping amenable mutation (~13% of DMD)',
    mechanism: 'Antisense oligonucleotide (exon 51 skipping)',
    mechanism_category: 'antisense_oligonucleotide',
    molecular_target: 'Dystrophin pre-mRNA (exon 51)',
    phase: 'Approved',
    primary_endpoint: 'Dystrophin production',
    key_data: 'Pivotal study: 0.93% dystrophin at 48 weeks (vs 0.16% placebo); functional benefit debated',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First exon-skipping therapy approved', 'Addresses unmet need', 'Continuous dosing maintains effect'],
    weaknesses: ['Minimal dystrophin production', 'No confirmed functional benefit', 'Controversial FDA approval', 'Weekly IV infusion'],
    source: 'FDA label; Sarepta 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Emflaza',
    generic_name: 'deflazacort',
    company: 'PTC Therapeutics',
    indication: 'Duchenne Muscular Dystrophy',
    indication_specifics: 'DMD in patients aged 2 years and older (corticosteroid standard of care)',
    mechanism: 'Corticosteroid (anti-inflammatory, muscle preservation)',
    mechanism_category: 'corticosteroid',
    molecular_target: 'Glucocorticoid receptor',
    phase: 'Approved',
    primary_endpoint: 'Muscle strength preservation',
    key_data: 'Pivotal trial: maintained ambulation longer vs placebo; 52-week muscle strength benefit over prednisone in some measures',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Established corticosteroid standard of care', 'FDA-approved specifically for DMD', 'Less weight gain than prednisone'],
    weaknesses: ['All corticosteroid side effects (Cushingoid, bone loss)', 'Does not address underlying cause', 'Generic prednisone alternative available'],
    source: 'FDA label; PTC Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Givinostat',
    generic_name: 'givinostat',
    company: 'Italfarmaco',
    indication: 'Duchenne Muscular Dystrophy',
    indication_specifics: 'DMD in patients aged 6+ years (all mutation types)',
    mechanism: 'HDAC inhibitor (reduces fibrosis and fat replacement in muscle)',
    mechanism_category: 'hdac_inhibitor',
    molecular_target: 'Class I/II HDACs',
    phase: 'Approved',
    primary_endpoint: 'Muscle function (4-stair climb, NSAA)',
    key_data: 'EPIDYS: 4SC velocity -1.78 vs -4.02 stairs/sec decline (placebo); reduced muscle fat fraction on MRI',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Mutation-agnostic mechanism', 'Oral administration', 'Addresses fibrosis/inflammation pathway', 'Add-on to corticosteroids'],
    weaknesses: ['GI side effects (diarrhea)', 'Thrombocytopenia monitoring', 'Modest functional benefit', 'Long-term data limited'],
    source: 'FDA label; EPIDYS trial; Italfarmaco 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // SICKLE CELL DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Casgevy',
    generic_name: 'exagamglogene autotemcel',
    company: 'Vertex/CRISPR Therapeutics',
    indication: 'Sickle Cell Disease',
    indication_specifics: 'SCD in patients aged >= 12 years with recurrent vaso-occlusive crises',
    mechanism: 'Ex vivo CRISPR/Cas9 gene-edited autologous stem cell therapy (reactivates fetal hemoglobin)',
    mechanism_category: 'gene_therapy',
    molecular_target: 'BCL11A (erythroid enhancer)',
    phase: 'Approved',
    primary_endpoint: 'VOC-free duration',
    key_data: 'CLIMB SCD-121: 97% of patients VOC-free for >= 12 consecutive months post-infusion; total Hb normalized',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First CRISPR therapy approved', 'Potentially curative', 'Dramatic VOC elimination', 'Fetal Hb induction'],
    weaknesses: ['$2.2M price', 'Requires myeloablative conditioning', 'Apheresis and manufacturing complexity', 'Infertility risk from conditioning'],
    source: 'FDA label; CLIMB SCD-121 trial; Vertex/CRISPR 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lyfgenia',
    generic_name: 'lovotibeglogene autotemcel',
    company: 'bluebird bio',
    indication: 'Sickle Cell Disease',
    indication_specifics: 'SCD in patients aged >= 12 years with recurrent VOC',
    mechanism: 'Ex vivo lentiviral gene therapy (adds anti-sickling beta-globin gene)',
    mechanism_category: 'gene_therapy',
    molecular_target: 'Beta-globin (anti-sickling HbAT87Q)',
    phase: 'Approved',
    primary_endpoint: 'VOC-free duration',
    key_data: 'Phase 1/2: 94% of patients VOC-free at 6-18 months; HbAT87Q production sustained',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Gene addition approach (not editing)', 'Sustained anti-sickling hemoglobin', 'One-time treatment'],
    weaknesses: ['Hematologic malignancy risk (boxed warning)', 'Myeloablative conditioning required', '$3.1M price', 'bluebird bio financial concerns'],
    source: 'FDA label; Phase 1/2 data; bluebird bio 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Oxbryta',
    generic_name: 'voxelotor',
    company: 'Pfizer (ex-Global Blood Therapeutics)',
    indication: 'Sickle Cell Disease',
    indication_specifics: 'SCD in adults and children >= 4 years (hemoglobin polymerization inhibitor)',
    mechanism: 'HbS polymerization inhibitor (allosteric modifier of hemoglobin oxygen affinity)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'Hemoglobin S',
    phase: 'Approved',
    primary_endpoint: 'Hemoglobin response',
    key_data: 'HOPE: Hb increase >= 1 g/dL in 51% vs 7% placebo; reduced hemolysis markers',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First disease-modifying oral therapy targeting polymerization', 'Hemoglobin improvement', 'Oral daily dosing'],
    weaknesses: ['Voluntarily withdrawn from market (Sept 2024) due to lack of VOC benefit in HOPE-KIDS 2', 'Hb improvement did not translate to clinical outcomes'],
    source: 'FDA label; HOPE trial; Pfizer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Adakveo',
    generic_name: 'crizanlizumab',
    company: 'Novartis',
    indication: 'Sickle Cell Disease',
    indication_specifics: 'Reduction of frequency of VOC in SCD patients aged >= 16 years',
    mechanism: 'Anti-P-selectin monoclonal antibody',
    mechanism_category: 'anti_selectin',
    molecular_target: 'P-selectin',
    phase: 'Approved',
    primary_endpoint: 'Annual rate of VOC',
    key_data: 'SUSTAIN: median VOC 1.63 vs 2.98 per year (45.3% reduction); STAND confirmatory mixed results',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First targeted VOC prevention therapy', 'Anti-adhesion mechanism addresses pathophysiology', 'IV monthly dosing'],
    weaknesses: ['STAND confirmatory trial missed primary endpoint', 'EU withdrawal', 'Modest effect size', 'Future uncertain post-STAND'],
    source: 'FDA label; SUSTAIN trial; Novartis 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // TRIPLE NEGATIVE BREAST CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Keytruda + Chemo',
    generic_name: 'pembrolizumab + chemotherapy',
    company: 'Merck',
    indication: 'Triple Negative Breast Cancer',
    indication_specifics: 'Neoadjuvant/adjuvant early-stage TNBC; 1L metastatic TNBC PD-L1 CPS >= 10',
    mechanism: 'PD-1 inhibitor + chemotherapy',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'pCR / PFS',
    key_data: 'KEYNOTE-522: pCR 64.8% vs 51.2% with pembro+chemo neo/adj; KEYNOTE-355: mPFS 9.7 vs 5.6 mo (CPS>=10)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Standard-of-care in early and metastatic TNBC', 'pCR rates in neoadjuvant', 'Broad TNBC franchise'],
    weaknesses: ['Limited benefit in CPS < 10 metastatic', 'Chemotherapy backbone toxicity', 'Not all patients respond to IO'],
    source: 'FDA label; KEYNOTE-522/355 trials; Merck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Trodelvy',
    generic_name: 'sacituzumab govitecan',
    company: 'Gilead',
    indication: 'Triple Negative Breast Cancer',
    indication_specifics: '2L+ unresectable locally advanced or metastatic TNBC after >= 2 prior systemic therapies',
    mechanism: 'ADC (Trop-2)',
    mechanism_category: 'adc',
    molecular_target: 'TROP2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ASCENT: PFS 5.6 vs 1.7 mo vs chemo (HR 0.41); OS 12.1 vs 6.7 mo (HR 0.48)',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Dramatic PFS and OS benefit in 2L+ TNBC', 'Biomarker-independent activity', 'First Trop-2 ADC in TNBC'],
    weaknesses: ['Neutropenia and diarrhea', 'IV every-3-week infusion', 'No biomarker for patient selection'],
    source: 'FDA label; ASCENT trial; Gilead 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lynparza',
    generic_name: 'olaparib',
    company: 'AstraZeneca/Merck',
    indication: 'Triple Negative Breast Cancer',
    indication_specifics: 'Adjuvant HER2-negative high-risk early BC with germline BRCA mutation; metastatic gBRCA+ BC',
    mechanism: 'PARP inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'PARP1/2',
    phase: 'Approved',
    primary_endpoint: 'iDFS / PFS',
    key_data: 'OlympiAD: mPFS 7.0 vs 4.2 mo (HR 0.58) in mBC gBRCA+; OlympiA: adjuvant iDFS HR 0.58',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Standard in gBRCA+ TNBC', 'Adjuvant survival benefit', 'Oral monotherapy'],
    weaknesses: ['Limited to gBRCA+ (~10-15% of TNBC)', 'MDS/AML risk', 'Hematologic toxicity management'],
    source: 'FDA label; OlympiAD/OlympiA trials; AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Enhertu',
    generic_name: 'trastuzumab deruxtecan',
    company: 'Daiichi Sankyo/AstraZeneca',
    indication: 'Triple Negative Breast Cancer',
    indication_specifics: 'HER2-low (IHC 1+ or IHC 2+/ISH-) metastatic TNBC (and other HER2-low BC)',
    mechanism: 'ADC (HER2)',
    mechanism_category: 'adc',
    molecular_target: 'HER2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'DESTINY-Breast04: HER2-low mPFS 9.9 vs 5.1 mo (HR 0.50); OS 23.4 vs 16.8 mo (HR 0.64)',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Opened HER2-low category', 'Active in TNBC subset with HER2-low', 'OS benefit demonstrated'],
    weaknesses: ['Not all TNBC is HER2-low (~60% are)', 'ILD/pneumonitis risk', 'IV administration'],
    source: 'FDA label; DESTINY-Breast04 trial; Daiichi Sankyo 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Dato-DXd',
    generic_name: 'datopotamab deruxtecan',
    company: 'Daiichi Sankyo/AstraZeneca',
    indication: 'Triple Negative Breast Cancer',
    indication_specifics: 'Locally recurrent inoperable or metastatic TNBC after prior systemic therapy',
    mechanism: 'ADC (Trop-2)',
    mechanism_category: 'adc',
    molecular_target: 'TROP2',
    phase: 'Phase 3',
    primary_endpoint: 'PFS',
    key_data: 'TROPION-Breast01: PFS 6.9 vs 4.9 mo vs chemo (HR 0.63) in HR+; TNBC expansion ongoing',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Next-gen Trop-2 ADC with potentially better tolerability', 'DXd payload differentiation', 'Expanding across BC subtypes'],
    weaknesses: ['Head-to-head vs Trodelvy data pending', 'ILD risk (lower than T-DXd but present)', 'Crowded ADC space in TNBC'],
    source: 'TROPION-Breast01 (NCT05104866); ASCO 2024',
    last_updated: '2024-12-01',
  },

  // ══════════════════════════════════════════════════════════
  // METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Xtandi',
    generic_name: 'enzalutamide',
    company: 'Pfizer/Astellas',
    indication: 'Metastatic Castration-Resistant Prostate Cancer',
    indication_specifics: 'mCRPC pre- and post-chemotherapy; metastatic CSPC; nmCRPC',
    mechanism: 'Androgen receptor inhibitor (2nd-generation)',
    mechanism_category: 'anti_androgen',
    molecular_target: 'Androgen Receptor',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'PREVAIL: mCRPC pre-chemo OS 35.3 vs 31.3 mo (HR 0.77); ARCHES: mCSPC rPFS HR 0.39',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Broadest prostate cancer label', 'Strong brand across disease states', 'Oral daily dosing'],
    weaknesses: ['Fatigue, cognitive effects', 'Seizure risk', 'Competition from abiraterone generics and darolutamide'],
    source: 'FDA label; PREVAIL/ARCHES trials; Pfizer/Astellas 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zytiga',
    generic_name: 'abiraterone acetate',
    company: 'Johnson & Johnson',
    indication: 'Metastatic Castration-Resistant Prostate Cancer',
    indication_specifics: 'mCRPC; mCSPC (high-volume, high-risk) with prednisone',
    mechanism: 'CYP17A1 inhibitor (androgen biosynthesis inhibitor)',
    mechanism_category: 'anti_androgen',
    molecular_target: 'CYP17A1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'COU-AA-301: post-chemo mCRPC OS 15.8 vs 11.2 mo (HR 0.74); LATITUDE: mCSPC OS HR 0.62',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Established standard in mCRPC', 'OS benefit in multiple settings', 'Generic now available (cost reduction)'],
    weaknesses: ['Requires prednisone co-administration', 'Mineralocorticoid excess (HTN, hypokalemia)', 'Hepatotoxicity monitoring'],
    source: 'FDA label; COU-AA-301/LATITUDE trials; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nubeqa',
    generic_name: 'darolutamide',
    company: 'Bayer',
    indication: 'Metastatic Castration-Resistant Prostate Cancer',
    indication_specifics: 'nmCRPC; mHSPC with docetaxel (ARASENS)',
    mechanism: 'Androgen receptor inhibitor (structurally distinct)',
    mechanism_category: 'anti_androgen',
    molecular_target: 'Androgen Receptor',
    phase: 'Approved',
    primary_endpoint: 'MFS / OS',
    key_data: 'ARAMIS: nmCRPC MFS 40.4 vs 18.4 mo (HR 0.41); ARASENS: mHSPC OS HR 0.68 with ADT+docetaxel',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Best-in-class tolerability (less fatigue, fewer CNS effects)', 'No BBB penetration', 'Flexible dosing'],
    weaknesses: ['Late entrant vs enzalutamide/abiraterone', 'Smaller market share', 'Requires docetaxel for mHSPC label'],
    source: 'FDA label; ARAMIS/ARASENS trials; Bayer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Pluvicto',
    generic_name: 'lutetium Lu 177 vipivotide tetraxetan',
    company: 'Novartis',
    indication: 'Metastatic Castration-Resistant Prostate Cancer',
    indication_specifics: 'PSMA-positive mCRPC after prior ARPI and taxane chemotherapy',
    mechanism: 'Radioligand therapy (PSMA-targeted)',
    mechanism_category: 'radioligand',
    molecular_target: 'PSMA',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'VISION: mOS 15.3 vs 11.3 mo vs SOC (HR 0.62); rPFS 8.7 vs 3.4 mo (HR 0.40)',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First PSMA radioligand therapy', 'OS benefit in heavily pretreated mCRPC', 'Novel modality expanding to earlier lines'],
    weaknesses: ['PSMA-PET imaging required for selection', 'Manufacturing/supply constraints', 'Bone marrow toxicity', 'Dry mouth/salivary gland toxicity'],
    source: 'FDA label; VISION trial; Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lynparza',
    generic_name: 'olaparib',
    company: 'AstraZeneca/Merck',
    indication: 'Metastatic Castration-Resistant Prostate Cancer',
    indication_specifics: 'mCRPC with HRR gene mutations (BRCA1/2, ATM, etc.) after prior ARPI',
    mechanism: 'PARP inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'PARP1/2',
    phase: 'Approved',
    primary_endpoint: 'rPFS',
    key_data: 'PROfound: BRCA1/2 rPFS 9.8 vs 3.0 mo (HR 0.22); OS benefit in BRCA1/2 cohort',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First precision oncology in prostate cancer', 'Dramatic rPFS in BRCA+', 'Oral monotherapy'],
    weaknesses: ['HRR mutations only ~25% of mCRPC', 'Anemia and fatigue', 'Genomic testing infrastructure required'],
    source: 'FDA label; PROfound trial; AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
];

// ────────────────────────────────────────────────────────────
// MERGED DATABASE (all therapy areas)
// ────────────────────────────────────────────────────────────

export const COMPETITOR_DATABASE: CompetitorRecord[] = [
  ...BASE_COMPETITORS,
  ...ONCOLOGY_EXTRA_COMPETITORS,
  ...NEUROLOGY_COMPETITORS,
  ...RARE_DISEASE_COMPETITORS,
  ...IMMUNOLOGY_COMPETITORS,
  ...CARDIO_METABOLIC_COMPETITORS,
  ...SPECIALTY_COMPETITORS_1,
  ...SPECIALTY_COMPETITORS_2,
  ...ADDITIONAL_COMPETITORS,
];

// ────────────────────────────────────────────────────────────
// QUERY HELPERS
// ────────────────────────────────────────────────────────────

/**
 * Returns all competitors for a given indication name.
 * Uses case-insensitive partial matching to handle synonyms and abbreviations.
 */
export function getCompetitorsForIndication(indicationName: string): CompetitorRecord[] {
  const normalized = indicationName.toLowerCase().trim();
  return COMPETITOR_DATABASE.filter(c =>
    c.indication.toLowerCase() === normalized ||
    c.indication.toLowerCase().includes(normalized) ||
    normalized.includes(c.indication.toLowerCase())
  );
}

/**
 * Returns a deduplicated list of mechanism categories present
 * among a set of competitor records.
 */
export function getUniqueMechanisms(competitors: CompetitorRecord[]): string[] {
  return Array.from(new Set(competitors.map(c => c.mechanism_category)));
}

/**
 * Returns competitors filtered by mechanism category.
 */
export function getCompetitorsByMechanism(mechanism: string): CompetitorRecord[] {
  const normalized = mechanism.toLowerCase().trim();
  return COMPETITOR_DATABASE.filter(c =>
    c.mechanism_category.toLowerCase() === normalized ||
    c.mechanism.toLowerCase().includes(normalized)
  );
}

/**
 * Returns competitors at a specific clinical phase.
 */
export function getCompetitorsByPhase(phase: ClinicalPhase): CompetitorRecord[] {
  return COMPETITOR_DATABASE.filter(c => c.phase === phase);
}

/**
 * Returns the set of unique indication names that have competitive coverage.
 * Useful for showing which indications have data in the UI.
 */
export function getCoveredIndications(): Set<string> {
  return new Set(COMPETITOR_DATABASE.map(c => c.indication));
}
